Introduction {#s1}
============

p27^Kip1^ is a cell cycle inhibitor that binds to a broad range of cyclin-CDK complexes ([@bib8]). p27-mediated cyclin-CDK inhibition involves the N-terminal extremity (aa 28--89) of the protein that allows interaction with both cyclin and CDK subunits ([@bib68]; [@bib8]). The critical role of p27 as a negative regulator of cell proliferation is underscored by the phenotype of p27 knockout mice, which exhibit a hyperproliferative phenotype in multiple tissues and are more susceptible to tumor development than wild-type animals ([@bib22]; [@bib37]; [@bib60]; [@bib6]; [@bib23]). While the tumor suppressive role of p27 is confirmed by the frequent loss of p27 expression in many types of cancers, p27 is also mislocalized in a fraction of tumors due to activation of various signaling pathways that cause its nuclear export and/or cytoplasmic retention ([@bib16]). Cytoplasmic p27 has been associated with decreased patient survival, high tumor grade and metastasis in several tumor types including breast carcinomas, acute myeloid leukemia, glioblastoma, melanoma and non-small cell lung carcinomas ([@bib48]; [@bib16]; [@bib45]; [@bib96]; [@bib56]; [@bib14]). The possibility that cytoplasmic p27 may confer a pro-tumorigenic advantage was confirmed in a mouse model expressing a mutant form of p27 that cannot bind cyclin-CDK complexes (p27CK-) ([@bib7]; [@bib83]). These mice are more susceptible than p27-null and wild-type mice to both spontaneous and induced tumor development, thus uncovering an oncogenic role for p27 in vivo ([@bib83]; [@bib7]).

It now appears that p27 is a multifunctional protein involved in the regulation of multiple cellular processes, some of which are regulated by p27 in a CDK-independent manner ([@bib8]; [@bib86]). Indeed, p27 has been implicated in the control of cell migration, transcriptional repression, autophagy, stem cell specification and differentiation, cytokinesis, and apoptosis ([@bib8]; [@bib86]; [@bib2]; [@bib5], [@bib7]; [@bib72]; [@bib84]; [@bib63]; [@bib46]; [@bib44]; [@bib62]; [@bib31]). This functional versatility may stem from the intrinsically disordered structure of p27, which folds upon binding to other proteins, allowing p27 to interact with a wide variety of partners ([@bib39]; [@bib25]). While these various functions participate in homeostasis in normal cells and tissues, they may be co-opted by tumor cells to promote oncogenesis.

Metastasis, the process whereby cells from a primary tumor disseminate throughout the body and form secondary tumors at distant sites, is the leading cause of cancer related death ([@bib85]). It requires tumor cells to migrate and invade through neighboring tissues, enter the blood flow and then extravasate to disseminate and form new tumors in host tissues ([@bib85]). Regulation of cell motility was the first CDK-independent role ascribed to p27 ([@bib59]; [@bib20]; [@bib5]). In the cytosol, p27 can interact with RhoA, preventing RhoA activation by guanine-nucleotide exchange factors (GEFs) and thereby modulating actin cytoskeleton dynamics and migration ([@bib4], [@bib5]). Consequently, mouse embryo fibroblasts (MEFs) lacking p27 have more RhoA activity, increased numbers of stress fibers and focal adhesions and exhibit a defect in migration ([@bib5]). This pathway is important for proper migration of bone marrow macrophages and developing cortical neurons and for cancer cell migration and invasion in vivo ([@bib27]; [@bib62]; [@bib69]; [@bib28]; [@bib95]; [@bib82]; [@bib41]; [@bib32]). p27 can also regulate cell migration by controlling microtubule stability through Stathmin or directly by binding to microtubules and promoting microtubule polymerization ([@bib2]; [@bib27]). In a 3D environment, cells adopt different strategies to migrate and invade through surrounding matrix ([@bib71]; [@bib85]). The mode of migration is influenced, at least in part, by the activities of Rho GTPases: RhoA activity favors an amoeboid migration, whereas Rac1 activity promotes mesenchymal migration ([@bib79]; [@bib89]). Accordingly, cytoplasmic p27 promotes mesenchymal migration via the inhibition of RhoA activity, while cells lacking p27 tend to adopt an amoeboid mode of migration ([@bib28]; [@bib3]). More recently, p27 was reported to promote epithelial to mesenchymal transition by binding to JAK2, promoting STAT3 activation and the upregulation of Twist1 ([@bib99]).

Here, we describe a novel mechanism by which p27 directly regulates invadopodia formation and cell invasion through extracellular matrix (ECM) via Cortactin. Invadosomes (designating both invadopodia and podosomes) are thought to allow cells to coordinate ECM degradation with migration within the tissue microenvironment ([@bib58]; [@bib49]; [@bib21]). Cortactin plays a key role in the formation of actin protrusive structures such as lamellipodia and invadosomes ([@bib58]; [@bib36]; [@bib52]). Cortactin has been involved in all steps of the invadosome lifecycle, from assembly, maturation, proteolytic activity and disassembly ([@bib52]; [@bib58]; [@bib57]). All these steps appear to be regulated by phosphorylation events on Cortactin ([@bib66]; [@bib57]; [@bib58]). Overall, Cortactin is a scaffold protein composed of an N-terminal acidic domain, followed by several actin-binding repeats allowing its interaction with F-actin, a Pro-rich region and a SH3 domain ([@bib52]; [@bib36]). Phosphorylation of Cortactin by Src and Abl family tyrosine kinases has two effects: first, this releases the actin severing protein Cofilin from an inhibitory interaction with Cortactin and generates actin barbed ends; second, Arp2/3, N-WASP and Nck1 are recruited onto Cortactin, promoting the polymerization of branched actin ([@bib66]; [@bib91]; [@bib67]). Dephosphorylation of Cortactin then allows the inhibition of Cofilin activity and stabilizes the invadopodia ([@bib66]). Cortactin also plays a key role in matrix metalloproteinase secretion in mature invadopodia ([@bib17]). Finally, invadopodia disassembly is induced by sequential activation of the Rac-GEF Trio, Rac1 and p21-Activated Kinase-1 (PAK1) pathway and presumably by PAK1-mediated phosphorylation of Cortactin on Ser113, since a Ser113 to Ala mutant blocked invadopodia disassembly ([@bib57]). How PAK-phosphorylated Cortactin mediates invadopodia disassembly is still unclear but could be due, at least in part, to a decreased affinity of Cortactin phosphorylated within its F-actin binding repeats (on S113, S150 and/or S282) for F-actin, potentially destabilizing the structure ([@bib93], [@bib92]).

We found that p27 binds to Cortactin and localizes to invadopodia following serum or growth factor stimulation and promotes cell invasion. Paradoxically, p27-null cells have more invadopodia and degrade gelatin more efficiently, but exhibit impaired invasive capacity. In fact, we found that p27 promotes the recruitment of PAK1 to Cortactin and invadopodia turnover and this is dependent on phosphorylation of S113/S150/S282 of Cortactin, the sites targeted by PAK kinases. Thus, in absence of p27, the dynamics of invadopodia is altered and prevents efficient invasion through ECM. Altogether, we have identified a novel mechanism by which p27 directly controls cell invasion that could contribute to the increased invasive and metastatic capacity of tumors where p27 is mislocalized in the cytoplasm.

Results {#s2}
=======

p27 interacts with Cortactin and localizes to invadopodia {#s2-1}
---------------------------------------------------------

While the role of p27 in the regulation of cell migration is firmly established, how p27 is targeted to specific locations in the cytoplasm to control motility and invasion remains unclear ([@bib28]; [@bib3]; [@bib4], [@bib5]; [@bib27]; [@bib62]; [@bib69]; [@bib95]; [@bib82]; [@bib41]; [@bib32]). We recently identified Cortactin in a proteomic screen in which protein arrays (Protoarray, ThermoFisher Scientific) were probed with recombinant human p27, indicating that the two proteins interact directly. We confirmed the binding of p27 to Cortactin in HEK 293 cells overexpressing p27 and Myc-tagged Cortactin ([Figure 1A](#fig1){ref-type="fig"}), as well as on endogenous proteins in Hela cells and MEFs immortalized with the human papilloma virus E6 protein ([Figure 1B](#fig1){ref-type="fig"}) ([@bib83]). The interaction domain of Cortactin on p27 was mapped by pull-down assays using various GST-p27 fusion proteins and Myc-Cortactin in HEK 293 cells. Cortactin bound to the p27CK- mutant, that cannot interact with cyclins and CDKs ([@bib6], [@bib7]), and to the C-terminal half (aa 88--198) of p27 but not the N-terminal half (aa 1--87) of the protein that contains the cyclin and CDK interaction domains ([Figure 1C and D](#fig1){ref-type="fig"}). The Cortactin interaction domain on p27 was narrowed down to the last 8 aa of p27, as a p27CK- 1--190 mutant did not interact with Cortactin any longer ([Figure 1E](#fig1){ref-type="fig"}). A p27CK- 1--197 mutant, lacking only the C-terminal threonine residue, still bound to Cortactin ([Figure 1E](#fig1){ref-type="fig"}), suggesting that phosphorylation on T198 is not needed for binding to Cortactin.10.7554/eLife.22207.003Figure 1.p27 binds to Cortactin.(**A--B**) Co-immunoprecipitation of p27 and Cortactin: (**A**) p27 was immunoprecipitated using rabbit anti-p27 (C19) antibodies from HEK293 lysates transfected with plasmids encoding p27, Myc-Cortactin (Myc-Cort) or both. (**B**) Immunoprecipitation of endogenous Cortactin using rabbit anti-Cortactin (H191) antibodies from HeLa or E6 MEF lysates, beads alone were used as control. (**A--B**) Co-immunoprecipitated proteins were detected by immunoblot with mouse anti-c-Myc (9E10) (**A**) or mouse anti-p27 (F-8) antibodies (**B**). Immunoprecipitated proteins were visualized by reprobing the membrane with mouse anti-p27 (F-8) (**A**) or with rabbit anti-Cortactin (H-191) antibodies and anti-rabbit Ig light-chain secondary antibodies (**B**). Immunoblots of extracts show the level of proteins in each condition. (**C--F**) Pull-down assays: HEK293 cells were transfected with Myc-Cortactin (**C--E**) or various deletion mutants of Myc-Cortactin (**F**) (ΔABR6, ΔABR5-6, ΔABR4-6, ΔABR3-6, ΔABR, ΔABR/NTA or ΔSH3, described in the schematic representation of Cortactin, bottom panel). NTA: N-Terminal acidic domain; ABR: actin binding repeat; Helix: helical domain; SH3: Src-homology three domain. Lysates were subjected to pull-down assays using GST, GST-p27 or GST-p27CK- (**C**), or GST, GST-p27, GST-p27 N~T~ (1-87) and GST-p27 C~T~ (88-198) (**D**), or GST, GST-p27CK-, GST-p27CK- (1-197) and GST-p27CK- (1-190) (**E**) or GST and GST-p27 (**F**). The amounts of Myc-Cortactin bound to the beads and of transfected protein present in the extracts were detected by immunoblot using mouse anti c-Myc (9E10) antibodies. The amounts of GST or GST p27 and mutants used in the assays were visualized by Coomassie staining of the gels. (**A--F**) All panels show representative results of at least three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.003](10.7554/eLife.22207.003)

Similarly, pull-down assays using full-length GST-p27 were performed on HEK 293 cell lysates expressing various Myc-tagged Cortactin truncation mutants to map the p27 interaction domain on Cortactin ([@bib34]). These experiments revealed that p27 interacts with the N-terminal half of Cortactin, within the actin binding repeats, as a mutant Cortactin lacking the actin binding repeats 3 to 6 (ΔABR3-6) did not bind p27 ([Figure 1F](#fig1){ref-type="fig"}).

Since Cortactin is a key component of invadopodia, we determined if p27 could colocalize with Cortactin in these structures. To remove most of soluble p27 prior to fixation and immunostaining, p27+/+E6 MEFs were permeabilized with digitonin, as described previously ([@bib84]). In these conditions, p27 could be readily observed in invadopodia where it colocalized with Tks5, a commonly used invadopodia marker ([@bib81]), or Cortactin ([Figure 2A and B](#fig2){ref-type="fig"}, respectively). The same approach was used to confirm p27 localization to invadopodia in human A549 lung adenocarcinoma and A375 melanoma cell lines ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).10.7554/eLife.22207.004Figure 2.p27 colocalizes with Cortactin in invadopodia.(**A--B**) p27+/+ MEFs were seeded on gelatin-coated coverslips for 24 hr. Cells were permeabilized with digitonin prior to fixation. Cells were labeled with mouse anti p27 (SX53G8.5) in red (**A--B**) and rabbit anti-Tks5 (M-300) (**A**) or rabbit anti-Cortactin (H-191) (**B**) in green. Images were acquired using a 60x objective and images displayed are cropped areas. Graphs displaying the fluorescence intensity (arbitrary unit) under the arrows in the enlarged panels were generated with the NIS Element software. Scale bars: 20 μm. (**C**) p27+/+ E6 MEFs were starved overnight in DMEM-0.1% FCS and then stimulated with growth medium for the indicated times. Cell lysates were subjected to immunoprecipitation using rabbit anti-p27 (C--19). Immunoprecipitated proteins and corresponding cell extracts were immunoblotted with rabbit anti-Cortactin (H--191) and mouse anti-p27 (F--8) antibodies. β-actin was used as loading control. The graph represents the mean fold change in amounts of Cortactin co-precipitated with p27 in each condition compared to time zero from five independent experiments. These differences were not statistically significant.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.004](10.7554/eLife.22207.004)10.7554/eLife.22207.005Figure 2---source data 1.Quantification of co-immunoprecipitation between p27 and Cortactin in MEF E6 ([Figure 2C](#fig2){ref-type="fig"}) and HeLa cells ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.005](10.7554/eLife.22207.005)10.7554/eLife.22207.006Figure 2---source data 2.Statistical analyses for [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.006](10.7554/eLife.22207.006)10.7554/eLife.22207.007Figure 2---figure supplement 1.p27 colocalizes with Cortactin and Tks5 in different tumor cell lines.(**A--C**) Twenty-four hr after seeding, A549 \[A-B\] or A375 cells \[C\] were permeabilized with digitonin prior to paraformaldehyde fixation. Cells were immunostained with mouse anti p27 (SX53G8.5) (red) \[A-C\] and with rabbit anti-Cortactin (H-191) \[A\] or rabbit anti-Tks5 (M-300) \[B-C\] (green) antibodies. Graphs display the fluorescence intensity (arbitrary unit) in the green and red channels over the distance depicted by the arrow in each enlarged area. Images were acquired using a 60x objective and images displayed are cropped areas. Measurements were made with the NIS Element software (Nikon). Scale bars: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.007](10.7554/eLife.22207.007)10.7554/eLife.22207.008Figure 2---figure supplement 2.p27/Cortactin interaction in HeLa cells after EGF stimulation.(**A**) HeLa cells were starved with DMEM 0.1% FCS overnight, stimulated with 100 ng/ml EGF (Peprotech) for the indicated times and cell lysates were submitted to co-immunoprecipitation using rabbit anti-p27 (C-19) antibodies. Co-immunoprecipitated proteins and total proteins in lysates were detected by immunoblot with anti-Cortactin and mouse anti-p27 (F-8) antibodies. β-actin was used as loading control. (**B**) The graph represents the mean fold change of Cortactin co-precipitated with p27 compared to time zero in three independent experiments. These differences were not statistically significant.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.008](10.7554/eLife.22207.008)

Invadopodium and podosome formation is stimulated by growth factors ([@bib58]). Growth factor stimulation causes the degradation of p27 as cells enter the cell cycle but also the relocalization of a fraction of p27 in the cytoplasm between 1 hr and 6 hr post-stimulation, dependent on the phoshorylation of p27 on Ser10 ([@bib6], [@bib5]; [@bib11]; [@bib30]; [@bib76]; [@bib18]). Consistent with the translocation of p27 in the cytoplasm and the formation of invadopodia after serum or growth factor stimulation, an increased association between p27 and Cortactin by co-immunoprecipitation at 1 hr and 3 hr post-stimulation in p27+/+E6 MEFs ([Figure 2C](#fig2){ref-type="fig"}) and in Hela cells ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) was observed in five and three independent experiments, respectively. However, due to variability in signal intensities among independent experiments, these differences were not statistically significant. Together, our data indicate that a fraction of cytoplasmic p27 localizes to invadopodia after growth factor stimulation, where it binds to Cortactin.

p27 regulates invadopodia formation and promotes invasion {#s2-2}
---------------------------------------------------------

Invadopodia and podosomes are capable of both adhering to and degrading ECM ([@bib58]; [@bib21]). Fibroblasts do not normally form invadosomes unless transformed by Src ([@bib58]). We first verified that the E6 immortalized MEF lines used in our study were forming functional, matrix degrading invadopodia. For this, p27+/+, p27−/− and p27CK-/CK- E6 MEFs were seeded on fluorescent gelatin and Tks5 immunostaining indicated that these cells could all form Tks5-containing structures that efficiently degraded gelatin ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). p27 colocalized with Tks5 at sites of gelatin degradation in MEFs and A549 cells, suggesting that p27 can be present at functional invadopodia ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Since p27 binds to Cortactin and can localize to invadopodia, we determined if p27 status influenced the ability of cells to form invadopodia. Counting of the number of cells forming invadopodia using Tks5 immunostaining ([Figure 3A](#fig3){ref-type="fig"}) revealed that while cells expressing p27 or p27CK- rarely formed invadopodia (5.83% and 8.68%, respectively), nearly half of MEFs lacking p27 had invadopodia (44.66%) ([Figure 3B](#fig3){ref-type="fig"}). In keeping with the number of invadopodia forming cells, measurement of the area of fluorescent gelatin degraded per cell showed that p27−/− cells had a dramatically increased capacity to degrade ECM compared to p27+/+ and p27CK-/CK- MEFs ([Figure 3C and D](#fig3){ref-type="fig"}).10.7554/eLife.22207.009Figure 3.p27 regulates invadopodia formation and matrix degradation.(**A**) p27+/+, p27CK−/CK− and p27−/− immortalized MEFs were seeded on Oregon green-gelatin (gelatin-A488) for 16 hr. Cells were stained with rabbit anti-Tks5 (M-300) to visualize invadopodia. (**B**) The percentage of cells forming invadopodia was determined in a minimum of 15 fields, representing a minimum of 330 cells per genotype, for each experiment. The graph shows the mean of 3 independent experiments. (**C**) Cells were seeded as in (**A**). Tks5 staining shows invadopodia (red) and areas of degraded fluorescent gelatin indicate invadopodia activity (green). (**D**) The areas of degraded gelatin were measured in at least 15 fields per genotype in each experiment. The graph shows the mean of 3 independent experiments. (**E--G**) p27−/− E6 MEFs were infected with either empty vector or p27, p27CK− or p27CK− 1--190 vectors and then seeded on Gelatin-A488 for 48 hr. (**E**) p27 levels after retroviral infection were determined by immunoblot with rabbit anti-p27 (N-20) antibodies; Grb2 was used as loading control. (**F--G**) After Tks5 staining, invadopodia forming cells (**F**) were quantified as in B and area of degraded gelatin (**G**) as in D. Scale bars: 50 μm; 'ns' not significant; \*\*\*\*p\<0.0001. In A and C, images were acquired using a 40x objective and images displayed are cropped areas.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.009](10.7554/eLife.22207.009)10.7554/eLife.22207.010Figure 3---source data 1.Quantification of cells with invadopodia ([Figure 3B](#fig3){ref-type="fig"}); quantification of degraded gelatin area per cell ([Figure 3C](#fig3){ref-type="fig"}); quantification of cells with invadopodia after p27 re-expression ([Figure 3F](#fig3){ref-type="fig"}) and quantification of degraded gelatin area per cell after p27 re-expression ([Figure 3G](#fig3){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.010](10.7554/eLife.22207.010)10.7554/eLife.22207.011Figure 3---source data 2.Statistical analyses for [Figure 3B,C,F and G](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.011](10.7554/eLife.22207.011)10.7554/eLife.22207.012Figure 3---source data 3.Immunoblot scans of [Figure 3E](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.012](10.7554/eLife.22207.012)10.7554/eLife.22207.013Figure 3---figure supplement 1.p27+/+, p27CK−/CK− and p27−/− MEFs form functional invadopodia.HPV E6 immortalized p27+/+, p27CK−/CK− and p27−/− MEFs were seeded on Gelatin-A488 for 16 hr. Cells were fixed in paraformaldehyde and stained with rabbit anti-Tks5 (M-300; red) antibodies to visualize invadopodia. Images were acquired using a 60x objective and images displayed are cropped areas. Scale bars: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.013](10.7554/eLife.22207.013)10.7554/eLife.22207.014Figure 3---figure supplement 2.p27 colocalizes with Tks5 at sites of gelatin degradation.HPV E6 immortalized p27+/+ MEFs (**A**) or A549 lung adenocarcionma cells (**B**) were seeded on Gelatin-A488 and treated with 1 μM FRAX597 to stabilize invadopodia after 2 hr. After 72 hr, cells were permeabilized with digitonin, fixed in paraformaldehyde and stained with mouse anti-p27 (SX53G8.5, red) and rabbit anti-Tks5 antibodies (M-300; purple) to visualize p27/Tks5 colocalization and sites of gelatin degradation. Images were acquired using a 60x objective and images displayed are cropped areas. Scale bars: 10 μm. Graphs display the fluorescence intensity (arbitrary unit) in each channel over the distance depicted by the arrows (NIS Element software, Nikon). (**C--D**) Profiles of Cortactin and p27 localization outside of gelatin degradation area in p27+/+ MEFs (**C**) and A549 cells (**D**). The graphs were generated by moving the arrows from panels A and B to regions without gelatin degradation.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.014](10.7554/eLife.22207.014)

To confirm the involvement of p27 in regulating invadopodia number and proteolytic activity, we retrovirally infected p27−/− E6 MEFs with either empty vector, wild-type (WT) p27, p27CK- or a p27CK- 1--190 truncation mutant ([@bib4]; [@bib84]) that cannot interact with Cortactin ([Figure 1E](#fig1){ref-type="fig"}). Expression levels of p27 in these infected cells were determined by immunoblot ([Figure 3E](#fig3){ref-type="fig"}). Quantification of the number of cells forming invadopodia and of the area of gelatin degraded per cell indicated that expression of WT p27 and p27CK- significantly decreased both the number of p27−/− cells forming invadopodia and their capacity to degrade gelatin, while the p27CK- 1--190 mutant had no effect ([Figure 3F and G](#fig3){ref-type="fig"}). Thus, our data suggests that p27 limits invadopodia formation and that the domain mediating its interaction with Cortactin is required for this function.

The finding that p27 knockout cells more frequently form invadopodia and exhibit increased ECM degradation activity was surprising given the previous reports that p27 promotes migration and invasion ([@bib20]; [@bib27]; [@bib62]; [@bib69]; [@bib28]; [@bib95]; [@bib82]; [@bib41]; [@bib32]; [@bib99]; [@bib5]). We compared the motility of p27+/+, p27−/− and p27CK-/CK- E6 MEFs in 2D scratch wound assays and p27−/− cells had a migration defect ([Figure 4A and B](#fig4){ref-type="fig"}), in agreement with our previous findings ([@bib5]). We next measured the capacity of these MEFs to invade through a layer of Collagen I in transwell inserts. Similar to 2D migration, 3D invasion was reduced in p27−/− MEFs compared to either WT p27 or p27CK- expressing cells ([Figure 4C and D](#fig4){ref-type="fig"}), consistent with previous reports ([@bib20]; [@bib28]; [@bib95]; [@bib82]; [@bib32]; [@bib99]). To confirm the involvement of p27 in regulating invasion, p27−/− E6 MEFs retrovirally infected with either empty vector, p27CK- or p27CK- 1--190 ([Figure 4E](#fig4){ref-type="fig"}, left panel) were subjected to transwell invasion assays. While p27CK- restored invasion of p27−/− cells, the p27CK- 1--190 mutant had no effect ([Figure 4E](#fig4){ref-type="fig"}, right panel). Taken together our results indicate that although p27 limits the number of invadopodia in MEFs, it also promotes cellular invasion through ECM. On the other hand, while p27-null cells more frequently form invadopodia and exhibit an increased capacity to degrade ECM, their ability to invade through matrix was significantly impaired.10.7554/eLife.22207.015Figure 4.p27 promotes cell migration and invasion.(**A**) Representative images of scratch wound migration assays with p27+/+, p27CK−/CK− and p27−/− immortalized MEFs. Dark grey areas show the initial wound masks and dotted lines the migration fronts. Scale bars: 300 μm. (**B**) Mean cell migration at 12 hr and 24 hr post wounding for each genotype of five independent experiments. Percent of area in which the cells migrated, or wound closing (relative wound density) was calculated with the Incucyte software. 'ns': not significant; \*\*\*\*p\<0.0001. (**C**) Representative images of p27+/+, p27CK−/CK− and p27−/− immortalized MEFs that invaded through a layer of Collagen I in transwell invasion assays and migrated to the bottom side of the transwell membrane after 48 hr. Scale bars: 100 μm. (**D**) The graph shows the mean number of cells that invaded through Collagen I quantified by XTT staining, expressed relative to p27+/+ cells, of three independent experiments. \*\*p\<0.01. (**E**) p27−/− E6 MEFs were infected with either empty vector, p27CK- or p27CK- 1--190 vectors and used in transwell invasion assays as in (**C--D**). p27 levels after retroviral infection were determined by immunoblot with mouse anti-p27 (SX53G8.5); β-actin was used as loading control. The graph shows the mean number of cells that invaded through Collagen I quantified by XTT staining, expressed relative to p27−/− cells, of four independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.015](10.7554/eLife.22207.015)10.7554/eLife.22207.016Figure 4---source data 1.quantification of relative wound density ([Figure 4B](#fig4){ref-type="fig"}); quantification of invasion ([Figure 4D](#fig4){ref-type="fig"}); and quantification of invasion rescue by p27 re-expression ([Figure 4E](#fig4){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.016](10.7554/eLife.22207.016)10.7554/eLife.22207.017Figure 4---source data 2.Statistical analyses for [Figure 4B,D and E](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.017](10.7554/eLife.22207.017)

p27 promotes the interaction of Cortactin with PAK1 {#s2-3}
---------------------------------------------------

Interestingly, a similar, seemingly paradoxical finding was recently reported, in which inhibition of Rac1, Trio or PAK1 with siRNAs caused a dramatic increase in invadopodia lifetime and in their capacity to degrade matrix, but this was accompanied by a sharp decrease in cell invasion ([@bib57]). In this study, activation of the Trio/Rac1/PAK1 pathway induced a putative PAK1-mediated phosphorylation of Cortactin and invadopodia disassembly, as expression of a S113A Cortactin mutant blocked this pathway ([@bib57]). In this study, altering the dynamics of invadopodia turnover inhibited invasion ([@bib57]).

To find out whether p27-null cells more frequently form invadopodia than p27+/+ cells ([Figure 3A and B](#fig3){ref-type="fig"}) due to an increase in their lifetime, we infected p27+/+ and p27−/− MEFs with Tks5-GFP to visualize invadopodia in live cells. Videomicroscopy analyses revealed that while invadopodia lifetime was on average 16.7 min in p27+/+ cells, their mean duration was 65.9 min in p27−/− cells ([Figure 5A](#fig5){ref-type="fig"}). Thus, invadopodia appear more stable in cells lacking p27.10.7554/eLife.22207.018Figure 5.p27 promotes binding of Cortactin to PAK1.(**A**) Live p27+/+ and p27−/− immortalized MEFs expressing eGFP-Tks5 were imaged by videomicroscopy to measure invadopodia lifetime, using Tks5 as an invadopodia marker. The graph represents the average invadopodia lifetime of 20 invadopodia per genotype per experiment from three independent experiments. (**B--C**) Co-immunoprecipitations using rabbit anti-PAK1 (N-20) of HeLa cell lysates transfected with empty vector or p27 encoding vector (**B**) or p27+/+ and p27−/− E6 MEF lysates (**C**). Co-immunoprecipitated Cortactin was detected with mouse (**B**) or rabbit (**C**) anti-Cortactin antibodies. Immunoprecipitated PAK1 was visualized by reprobing the membranes with rabbit anti-PAK1 (N-20) and anti-Rabbit Ig light-chain secondary antibodies. Immunoblots of extracts show the level of proteins in each condition. In (**C**), the graph shows the mean fold change in the ratio of Cortactin to PAK1 co-immunoprecipitated, expressed relative to p27+/+ cells, in three independent experiments. \*\*p\<0.01. (**D**) p27+/+E6 MEFs were starved overnight in DMEM 0.1% FCS and then stimulated with growth medium for the indicated times. PAK1 was immunoprecipitated from cell lysates using rabbit anti-PAK1 (N-20). Immunoblots of immunoprecipitates (left panels) and extracts (right panels) were probed successively with rabbit anti-Cortactin (H-191) and anti-rabbit Ig light chain secondary antibodies and then with mouse anti-PAK1 (A6) antibodies. β-actin was used as loading control. (**E**) The graph shows the mean amount of Cortactin bound to PAK1 at each time-point from four independent experiments, normalized to time zero. These differences were not statistically significant. (**F**) p27+/+ MEFs were seeded on coverslips and permeabilized with digitonin prior to fixation. Cells were labeled with rabbit anti-PAK1 (N-20, green) and mouse anti p27 (SX53G8.5, red) antibodies. Images were acquired using a 60x objective and images displayed are cropped areas. The graph displaying the fluorescence intensity (arbitrary unit) under the arrow in the enlarged panel was generated with NIS Element software. Scale bars: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.018](10.7554/eLife.22207.018)10.7554/eLife.22207.019Figure 5---source data 1.Quantification of invadopodia lifetime ([Figure 5A](#fig5){ref-type="fig"}); quantification of co-immunoprecipitation between Cortactin and PAK1 in MEFs ([Figure 5C](#fig5){ref-type="fig"}); and quantification of co-immunoprecipitation between Cortactin and PAK1 after serum stimulation ([Figure 5E](#fig5){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.019](10.7554/eLife.22207.019)10.7554/eLife.22207.020Figure 5---source data 2.Statistical analyses for [Figure 5A](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.020](10.7554/eLife.22207.020)10.7554/eLife.22207.021Figure 5---source data 3.Statistical analyses for [Figure 5C](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.021](10.7554/eLife.22207.021)10.7554/eLife.22207.022Figure 5---source data 4.Statistical analyses for [Figure 5E](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.022](10.7554/eLife.22207.022)10.7554/eLife.22207.023Figure 5---figure supplement 1.p27 does not affect Cortactin acetylation or the recruitment of c-Src, Arp2 and ERK1 to Cortactin.(**A**) HEK 293 cells were transfected with either empty vector, p27 or p27CK- coding vectors. Lysates were used for immunoblot with rabbit anti-Acetyl-Cortactin (BD-Transduction Laboratories), anti-Cortactin (H-191) and anti-p27 (C-19) antibodies. (**B--D**) Co-immunoprecipitations were performed using rabbit anti-Cortactin (H-191) in HeLa cell lysates transfected with either empty vector or p27 coding vector. Co-immunoprecipitated proteins were detected with rabbit anti-Arp2 (H-84) (**B**), anti-c-Src (SRC2) (**C**) or anti-ERK1 (K-23) (**D**). The immunoprecipitated proteins were visualized by reprobing the membrane with rabbit anti-Cortactin (H-191) and anti Rabbit Ig light-chain secondary antibodies. Immunoblots of extracts show the levels of proteins of interest in each condition. Experiments were performed at least three times, except only twice for \[D\].**DOI:** [http://dx.doi.org/10.7554/eLife.22207.023](10.7554/eLife.22207.023)

To determine whether p27 affects invadopodia formation through the regulation of Cortactin, we tested if binding of p27 to Cortactin regulated the interaction of Cortactin with some of its partners. p27 overexpression in Hela cells had no effect on the interaction of Cortactin with c-Src, ERK1 or Arp2 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) ([@bib36]). Also, Cortactin acetylation levels did not change when p27 was overexpressed ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), suggesting that p27 did not affect the interaction of Cortactin with acetyltransferases such as p300, Tip60 and ATAT1 or the deacetylases HDAC6 and Sirt1 ([@bib88]; [@bib97], [@bib98]; [@bib12]). In contrast, the presence of p27 increased the amount of Cortactin co-immunoprecipitated with PAK1 in Hela cells ([Figure 5B](#fig5){ref-type="fig"}). Conversely, in MEFs lacking p27, the amount of Cortactin co-precipitated with PAK1 was sharply decreased compared to p27+/+ cells, despite the fact that PAK1 levels were elevated in p27−/− cells ([Figure 5C](#fig5){ref-type="fig"}). Monitoring the kinetics of association of PAK1 with Cortactin in MEFs revealed that some PAK1 is already associated with Cortactin in serum starved cells, consistent with a previous report ([@bib90]) and progressively increase after serum stimulation, reaching a maximal level after 3 hr ([Figure 5D and E](#fig5){ref-type="fig"}); mirroring the kinetics of association of p27 with Cortactin ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). These results suggest that p27 binding to Cortactin promotes the association of PAK1 with Cortactin. Immunostaining of p27+/+ MEFs showed a colocalization of PAK1 and p27 at structures resembling invadopodia ([Figure 5F](#fig5){ref-type="fig"}). However, despite repeated attempts on both endogenous and overexpressed proteins, we were unable to obtain evidence supporting an interaction between p27 and PAK1 (data not shown).

p27 regulates invadopodia formation via the Rac1/PAK1/phospho-Cortactin pathway {#s2-4}
-------------------------------------------------------------------------------

p27 promotes the interaction of PAK1 with Cortactin ([Figure 5A--D](#fig5){ref-type="fig"}), which in turn may promote invadopodia disassembly by phosphorylating Cortactin on Ser113 ([@bib57]). To test whether PAK1 activity is responsible for the low number of invadopodia observed in p27+/+ MEFs, we monitored the effect of either silencing PAK1 with siRNA or of the PAK1-3 specific inhibitors FRAX597 ([@bib47]), FRAX1036 ([@bib65]) and G-5555 ([@bib61]) on invadopodia formation and activity. While PAK1 silencing or the PAK1-3 inhibitors dramatically increased both the number of cells forming invadopodia and the area of matrix degraded per cell in p27+/+ MEFs, as reported previously ([@bib57]), it had no effect in p27−/− cells ([Figure 6A--B,D--F](#fig6){ref-type="fig"}, and [Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}). PAK1 silencing was verified by immunoblot for PAK1 in Control or PAK1 siRNA treated cells ([Figure 6C](#fig6){ref-type="fig"}). The efficacy of FRAX597, FRAX1036 and G-5555 in inhibiting PAK1 was evaluated by immunoblot on either vehicle or inhibitor treated cells using phospho-Ser144 PAK1/Ser141-PAK2 antibodies ([Figure 6G](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}) ([@bib15]). These results suggest that p27 acts downstream of PAK1 in the regulation of invadopodia formation and activity, and that this pathway is impaired in p27−/− cells, possibly due to decreased PAK1/Cortactin interaction.10.7554/eLife.22207.024Figure 6.p27 regulates invadopodia formation downstream of PAK1.(**A--B**) p27+/+ and p27−/− E6 MEFs were seeded on gelatin-A488 and transfected with either control siRNAs or PAK1 siRNAs for 48 hr. Cells were stained with rabbit anti-Tks5 (M-300) to visualize invadopodia. At least ten fields per conditions were used to count cells forming invadopodia (**A**), representing a minimum of 212 cells per genotype for each experiment, or to measure the area of degraded gelatin, expressed in fold-change compared to vehicle treated conditions (**B**). (**C**) PAK1 siRNA efficacy at 48 hr was evaluated by immunoblot with rabbit anti-PAK1 (N-20) antibodies. β-actin was used as loading control. (**D--F**) p27+/+ and p27−/− E6 MEFs were seeded for 48 hr on gelatin-A488 and after 1 hr were treated with DMSO or 1 μM FRAX597, a PAK1-3 inhibitor. Quantification of cells forming invadopodia (**D**) and gelatin degradation (**E**) was performed as in (**A--B**), with a minimum of 215 cells counted per genotype per experiment. (**F**) Images were acquired using a 40x objective and images displayed are cropped areas. Scale bars: 50 μm. (**G**) FRAX597 inhibitor efficacy was evaluated by immunoblot with rabbit anti-phospho-Ser144-PAK1/phospho-Ser141-PAK2 and rabbit anti-PAK1 (N-20) antibodies. (**A--B**; **D--E**) The graphs show the mean of at least three independent experiments. \*\*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.024](10.7554/eLife.22207.024)10.7554/eLife.22207.025Figure 6---source data 1.Quantification of invadopodia forming cells ([Figure 6A](#fig6){ref-type="fig"}) and degraded gelatin area ([Figure 6B](#fig6){ref-type="fig"}) after PAK1 silencing; quantification of invadopodia forming cells ([Figure 6D](#fig6){ref-type="fig"}) and degraded gelatin area ([Figure 6E](#fig6){ref-type="fig"}) after FRAX597 treatment; quantification of invadopodia forming cells ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) and degraded gelatin area ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}) after FRAX1036 and G-5555 treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.025](10.7554/eLife.22207.025)10.7554/eLife.22207.026Figure 6---source data 2.statistical analyses for [Figure 6A,B,D and E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.026](10.7554/eLife.22207.026)10.7554/eLife.22207.027Figure 6---figure supplement 1.p27 regulates invadopodia formation in a PAK1 dependent manner.(**A--B**) p27+/+ or p27−/− E6 MEFs were seeded for 48 hr on Gelatin-A488 and treated 1 hr after seeding with either DMSO,1 μM FRAX1036 or 1 μM G-5555, two PAK1-3 inhibitors. Cells were stained with rabbit anti-Tks5 (M-300) to visualize invadopodia. The graphs show the mean of 3 independent experiments. For each experiment, at least ten fields per conditions were used to count cells forming invadopodia, representing a minimum of 168 cells per genotype (**A**), or to measure the area of degraded gelatin, expressed in fold-change compared to vehicle treated conditions (**B**). (**C**) The efficacy of PAK inhibitors was evaluated by immunoblot with rabbit anti-phospho-Ser144-PAK1/phospho-Ser141-PAK2 and Rabbit anti-PAK1 antibodies. Reprobing of membranes with a mouse anti-β actin antibody was used to control protein loading.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.027](10.7554/eLife.22207.027)

If p27 acts on the invadopodia disassembly pathway at the level of PAK1/Cortactin, one would not expect to see any difference in Rac1 activation levels in p27+/+ and p27−/− cells. This is what was observed by GTP-Rac1 pull-down assays ([Figure 7A](#fig7){ref-type="fig"}), in agreement with our previous observations ([@bib5]). Nevertheless, to further characterize how the Rac1/PAK1/Cortactin signaling pathway is affected in function of p27 status, we inhibited Rac1 itself using either Rac1 siRNAs ([Figure 7B--D](#fig7){ref-type="fig"}) or the Rac specific inhibitor NSC23766 ([@bib26]) ([Figure 7E and F](#fig7){ref-type="fig"}). Rac1 silencing by siRNAs was verified by immunoblot for Rac1 ([Figure 7D](#fig7){ref-type="fig"}). When Rac1 was silenced or inhibited, more p27+/+ cells formed invadopodia and there was a dramatic increase in the area of matrix degraded ([Figure 7B,E and C,F](#fig7){ref-type="fig"}, respectively), as reported previously ([@bib57]). On the other hand, in p27−/− cells, Rac1 silencing or inhibition had no effect on invadopodia formation or gelatin degradation ([Figure 7B,E and C,F](#fig7){ref-type="fig"}, respectively); supporting the idea that p27 regulates invadopodia disassembly downstream of Rac1 and PAK1.10.7554/eLife.22207.028Figure 7.p27 regulates invadopodia formation downstream of Rac1.(**A**) Cells were seeded for 24 hr and Rac1-GTP levels measured by GTP pull-downs assays using GST-PAK1-CD beads. The amounts of Rac1-GTP bound to the beads and of total Rac1 in the extracts were detected by immunoblot with mouse anti-Rac1. The graph shows the mean ratio of GTP-Rac1/total Rac1 from six independent experiments. (**B--D**) Cells were transfected with control (ctl) or Rac1 \#1 or \#2 siRNAs for 3 days. Cells were then seeded on Gelatin-A488 for 48 hr and for monitoring siRNA efficiency. Cells were stained with rabbit anti-Tks5 (M-300) to visualize invadopodia. At least ten fields per condition were used to count cells forming invadopodia, representing a minimum of 197 cells per genotype for each experiment (**B**) or to measure the area of degraded gelatin, expressed in fold-change compared to control siRNA treated conditions (**C**). (**D**) Rac1 silencing was evaluated by immunoblot with mouse anti-Rac1. β-actin was used as loading control. (**E--F**) Cells were processed as described in [Figure 6D and E](#fig6){ref-type="fig"} except that the Rac1 inhibitor NSC23766 at 100 μM was used instead of FRAX597. A minimum of 153 cells were counted per genotype for each experiment. (**B--C**; **E--F**) The graphs show the mean of at least three independent experiments. \*\*\*\*p\<0.0001; \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.028](10.7554/eLife.22207.028)10.7554/eLife.22207.029Figure 7---source data 1.Quantification of Rac1 GTP/Rac1 levels ([Figure 7A](#fig7){ref-type="fig"}); quantification of invadopodia forming cells ([Figure 7B](#fig7){ref-type="fig"}) and degraded gelatin area ([Figure 7C](#fig7){ref-type="fig"}) after silencing of Rac1; quantification of invadopodia forming cells ([Figure 7E](#fig7){ref-type="fig"}) and degraded gelatin area ([Figure 7F](#fig7){ref-type="fig"}) after NSC23766 treatment; quantification of invadopodia forming cells ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) and degraded gelatin area ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) after RhoA silencing; and quantification of invasion after Y27632 treatment ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.029](10.7554/eLife.22207.029)10.7554/eLife.22207.030Figure 7---source data 2.Statistical analyses for [Figure 7A,B,C,E,F](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A,B and D](#fig7s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.030](10.7554/eLife.22207.030)10.7554/eLife.22207.031Figure 7---figure supplement 1.RhoA regulation by p27 is not involved in invadopodia formation.(**A--C**) p27+/+ and p27−/− immortalized MEFs were transfected with siRNA control (ctl) or siRNA RhoA \#1 or \#2. After 3 days, cells were seeded on Gelatin-A488 for matrix degradation and for controlling siRNA efficiencies, for 48 hr. Cells were stained with rabbit anti-Tks5 (M-300) to visualize invadopodia. For each experiment, ten fields per condition, representing a minimum of 256 cells per genotype, were used to count invadopodia forming cells (**A**) or the area of degraded gelatin per cell (**B**). The graphs show the means of at least three independent experiments. (**C**) siRNA efficiency was evaluated by immunoblot with mouse anti-RhoA (26C4) antibodies. β-actin was used as loading control. (**D**) p27+/+ and p27−/− immortalized MEFs were subjected to invasion assays as in [Figure 4C--D](#fig4){ref-type="fig"} in presence or absence of the ROCK inhibitor Y27632 (10 μM). The graph shows the fold change in invasion relative to vehicle treated cells (-) from three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.031](10.7554/eLife.22207.031)

We previously reported that p27 binds RhoA and prevents its activation by its GEFs; consequently, cells lacking p27 have elevated RhoA activity ([@bib5]). Since RhoA plays a critical role in cell motility and the control of actin cytoskeleton dynamics, we determined whether RhoA was involved in p27-mediated regulation of invadopodia formation and function. Transfection of RhoA siRNAs in p27+/+ and p27−/− MEFs did not alter the proportion of cells forming invadopodia ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) and only mildly increased the ability of both p27+/+ and p27−/− cells to degrade ECM, although this was not statistically significant ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). RhoA siRNA efficacy was checked by immunoblot ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Furthermore, inhibition of the Rho effectors ROCK1/2 with a pharmacological inhibitor (Y27632) did not affect the ability of p27+/+ and p27−/− cells to invade through Collagen I in transwell invasion assays ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). Thus, in MEFs, depletion of RhoA did not affect the ability of cells to form invadopodia and slightly increased invadopodia proteolytic activity independently of p27 status.

Evidence suggests that invadopodia disassembly by the Trio/Rac1/PAK1 signaling pathway is mediated by phosphorylation of Cortactin on Ser113 ([@bib92]; [@bib57]). In the latter study, expression of an unphosphorylatable mutant of Cortactin (Cortactin S113A) increased both invadopodia lifetime and matrix degradation, as observed upon Rac1 or PAK1 silencing ([@bib57]). We retrovirally infected p27+/+ and p27−/− E6 MEFs with either empty vector, WT Cortactin, Cortactin S113A or the phosphomimetic mutant Cortactin S113D ([Figure 8A](#fig8){ref-type="fig"}) and monitored their effect on invadopodia formation and activity. In p27+/+ cells, Cortactin S113A increased the number of cells forming invadopodia, as observed previously ([@bib57]), while Cortactin S113D had no effect ([Figure 8B and D](#fig8){ref-type="fig"}). In contrast, Cortactin S113A had no effect in p27−/− cells, confirming that the Rac1/PAK1/Cortactin pathway is defective in absence of p27 and that p27 acts upstream of Cortactin. On the other hand, expression of Cortactin S113D in p27−/− cells decreased the number of invadopodia forming cells and the area of degraded gelatin ([Figure 8C and E](#fig8){ref-type="fig"}), indicating that mimicking Cortactin phosphorylation rescues the phenotype caused by the absence of p27.10.7554/eLife.22207.032Figure 8.Mimicking phosphorylation of Cortactin restores invadopodia dynamics in p27−/− cells.(**A--E**) p27−/− E6 MEFs were infected with empty vector or with vectors encoding wild type Cortactin (WT), S113A-Cortactin (S113A) or S113D-Cortactin (S113D). (**A**) Cortactin levels after retroviral infection were determined by immunoblot with rabbit anti-Cortactin (H-191) antibodies. β-actin was used as loading control. (**B--E**) Cells were seeded on gelatin-A488 for 48 hr. After Tks5 staining, cells forming invadopodia (**B--C**), or the area of degraded gelatin, expressed in fold-change compared to WT Cortactin transfected cells (**D--E**), were quantified in at least ten fields per condition in each experiment, representing a minimum of 179 cells per genotype. The graphs show the means of at least three independent experiments. (**F--J**) p27−/− E6 MEFs were infected with empty vector or with vectors encoding WT Cortactin, Cortactin TA (S113A/S150A/S282A) or Cortactin TD (S113D/S150D/S282D). (**J**) Cortactin levels after retroviral infection were determined as in (**A**). (**G--J**) Cells were processed as in (**B--E**) to quantify cells forming invadopodia (**G--H**), or the area of degraded gelatin (**I--J**), with a minimum of 222 cells counted per genotype per experiment. The graphs show the means of 3 independent experiments. (**K**) Schematic representation of the Rac1/PAK1/phospho-Cortactin pathway involved in invadopodia turnover and matrix degradation and its proposed regulation by p27. \*\*\*\*p\<0.0001; \*\*\*p\<0.001; \*\*p\<0.01; \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.032](10.7554/eLife.22207.032)10.7554/eLife.22207.033Figure 8---source data 1.Quantification of cells forming invadopodia ([Figure 8B--C](#fig8){ref-type="fig"}) and degraded gelatin area ([Figure 8D--E](#fig8){ref-type="fig"}) after infection with S113 phospho-mutants of Cortactin; quantification of cells forming invadopodia ([Figure 8G--H](#fig8){ref-type="fig"}) and degraded gelatin area ([Figure 8I--J](#fig8){ref-type="fig"}) after infection with triple phospho-mutants of Cortactin; quantification of P-Ser Cortactin/Cortactin ratio ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.22207.033](10.7554/eLife.22207.033)10.7554/eLife.22207.034Figure 8---source data 2.Statistical analyses for [Figure 8](#fig8){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.034](10.7554/eLife.22207.034)10.7554/eLife.22207.035Figure 8---source data 3.Statistical analyses for [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.035](10.7554/eLife.22207.035)10.7554/eLife.22207.036Figure 8---source data 4.Mascot search results for Cortactin for [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.036](10.7554/eLife.22207.036)10.7554/eLife.22207.037Figure 8---figure supplement 1.Cortactin is phosphorylated on S113/S150 and/or S282 in vivo.(**A**) HEK 293 cells were tranfected with Myc-tagged Cortactin for 24 hr or left untransfected (**U**) and 3 μM FRAX597 was added for 12 hr where indicated. Cortactin was immunoprecipitated with anti-Myc antibodies (9E10) and resolved on SDS-PAGE and transferred on PVDF membranes. The amount of Ser-phosphorylated Cortactin was detected by immunoblot with a monoclonal antibody against phospho-serine (BD) and the total amount of immunoprecipitated Cortactin by reprobing with anti-Cortactin (H191) antibody. P-Ser and Cortactin band intensities were quantified with Image J to calculate ratios, normalized to one for the control condition. Extracts were probed for Cortactin and Grb2 was used as loading control. (**B**) Average ratio of P-Ser signal/Total Cortactin signals from three independent experiments. Error bars are s.e.m. \*\*p\<0.01. (**C**) HEK 293 cells were tranfected with either empty vector, wild-type Cortactin (WT), S113A Cortactin or S113A/S150A/S282A (TA) Cortactin for 24 hr. Cortactin was immunoprecipitated with anti-Cortactin (H191) antibodies and processed as in (**A**). Serine phosphorylation of Cortactin was evaluated with anti-Phospho-Ser antibodies (BD). This data is representative of three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.037](10.7554/eLife.22207.037)10.7554/eLife.22207.038Figure 8---figure supplement 2.Cortactin is phosphorylated on S150 in vivo upon PAK activation.MS/MS analysis of Cortactin immunoprecipitated from HEK 293 cells transfected either with Myc-Cortactin or Myc-Cortactin and Myr-SH3-2, the second SH3 domain of Nck1 fused to the myristoylation signal of Src, which activate PAK kinase. S150 phosphorylation was only detected from lysates in which PAK activtiy was stimulated by the presence of the Src-SH3-2 domain. (**A**) MS/MS spectrum annotation of the residues 148--161 from Uniprot database reference SRC8_HUMAN or Q14247 (Src substrate Cortactin) protein. MS-Fragmented peptide correspond to the m/z selection of 516.888, matching \[HASQKDYSSGFGGK +80 Da (HPO~3~)\]^3+^ among 691 spectrum matching 98 distinct sequences of the same protein. Measured fragment matching masses bearing the modified serine residue showing a loss of neutral mass (H~3~PO~4~) are indicated in yellow. Not all the annotations could fit in the figure. The table below gathers all the matching fragments. (**B**) Table of theoretical fragment masses for the residues 148--161 of Uniprot database reference SRC8_HUMAN or Q14247 (Src substrate Cortactin) protein. In red are experimental masses of m/z detection of 516.888 matching \[HApSQKDYSSGFGGK\]^3+^ from the above spectrum. (**C**) Table of possible matches of the same set of experimental data with the four possible and closest theoretical sequences. The best score matches the phosphorylation of the serine 150 among the residues 148--161 of Uniprot database reference SRC8_HUMAN or Q14247 (Src substrate Cortactin) protein. Site analysis percentage corresponds to the probability output from the PhosphoRS algorythm.**DOI:** [http://dx.doi.org/10.7554/eLife.22207.038](10.7554/eLife.22207.038)

Importantly, PAK3 was reported to phosphorylate Cortactin on several serine residues (S113, S150 and S282) within the actin binding repeats ([@bib93]) suggesting that multiple phosphorylation events may synergize to regulate Cortactin function. To test this possibility, we generated triple alanine mutant (TA) (S113A/S150A/S282A) and triple aspartic acid mutant (TD) (S113D/S150D/S282D) of Cortactin and expressed these constructs in p27+/+ and p27−/− E6 MEFs ([Figure 8F](#fig8){ref-type="fig"}). Cortactin TA and TD mutants gave essentially similar results as the Cortactin S113A and S113D mutants, respectively ([Figure 8G--J](#fig8){ref-type="fig"}). Nevertheless, in p27+/+ MEFs, the Cortactin TA mutant was more potent than Cortactin S113A to promote invadopodia formation (13.5% p27+/+ cells forming invadopodia with Cortactin S113A versus 23.3% with Cortactin TA) and activity (6.17 fold increase in area of degraded gelatin with Cortactin S113A versus 10.02 fold with Cortactin TA) ([Figure 8B](#fig8){ref-type="fig"} versus [Figure 8G](#fig8){ref-type="fig"} and [Figure 8D](#fig8){ref-type="fig"} versus [Figure 8I](#fig8){ref-type="fig"}, respectively). This data suggests that Cortactin phosphorylation on S150 and/or S282 also contribute with S113 to control invadopodia disassembly. To further confirm that PAK-mediated phosphorylation events on Cortactin are involved in this pathway, we evaluated Cortactin phosphorylation levels in HEK 293 cells expressing Myc-tagged Cortactin treated or not with the PAK1-3 inhibitor FRAX597. In presence of FRAX597, there was a 36% decrease in P-Ser Cortactin level ([Figure 8---figure supplement 1A and B](#fig8s1){ref-type="fig"}). This mild reduction in P-Ser levels is consistent with Cortactin also being a substrate for other Ser/Thr kinases such as ERK, Akt and PKC. The contribution of S113, S150 and S282 phosphorylation in the P-Ser signal observed in Cortactin immunoprecipitates was estimated in HEK 293 cells expressing either wild-type Cortactin, Cortactin S113A or Cortactin TA. P-Ser levels were reduced in Cortactin S113A immunoprecipitations compared to WT Cortactin and further decreased in Cortactin TA immunoprecipitates, confirming that phosphorylation of these sites contribute to the Cortactin P-Ser signal in vivo ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}). Finally, to show that Cortactin was phosphorylated in vivo on PAK-targeted sites (S113, S150 and/or S282), we performed mass spectrometry analyses on Cortactin. For this, HEK 293 cells were transfected with Myc-Cortactin alone or Myc-Cortactin and the myristoylated second SH3 domain of Nck1 (Myr-SH3-2), which was previously shown to activate PAK1 ([@bib50]; [@bib51]). MS/MS analyses from Cortactin immunoprecipitates indicated that Cortactin was phosphorylated on S150 ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). This phosphorylation was detected only in samples from cells co-expressing Cortactin and Myr-SH3-2 suggesting that PAK1 activation is required for this event. Although no phosphorylation was detected on S113 or S282 in these experiments, phosphoproteome analyses from other studies have previously shown that Cortactin is phosphorylated in vivo on S113, S150 and/or S282: S113 phosphorylation was detected in prostate cancer cells ([@bib13]), mouse brain ([@bib94]) and breast cancers ([@bib55]). Phosphorylation on S150 was identified in mouse renal cells and human liver ([@bib9]; [@bib75]) and in the present study. S282 phosphorylation was detected in mitotic cells and breast cancers ([@bib55]; [@bib64]; [@bib38]). Phosphorylation on all three sites have been detected in ovarian and breast cancer xenogratfs ([@bib54]).

Altogether, our results indicate that p27 promotes invadopodia turnover and cell invasion via the Rac1/PAK1/Phospho-Cortactin pathway. In contrast, in absence of p27, this pathway is largely defective, resulting in increased invadopodia stability and elevated matrix degradation, but impaired invasion.

Discussion {#s3}
==========

Our results indicate that p27 regulates invadopodia formation and activity by binding to Cortactin, probably via the regulation of invadopodia turnover mediated by a signaling pathway recently characterized whereby signaling through Trio/Rac1/PAK1/Cortactin induces the disassembly of invadopodia ([@bib57]). The main finding presented here is that p27 directly controls cellular invasion by impinging on this pathway through the promotion of the Cortactin/PAK1 interaction and the phosphorylation of Cortactin on Ser113, S150 and/or S282 by PAK. Indeed, inhibiting the pathway upstream of Cortactin, either with Rac1 and PAK1 inhibitors or siRNAs converted the phenotype of p27+/+ cells to that of p27−/− cells. Conversely, artificially activating this pathway at the level of Cortactin using phosphomimetic mutants for the PAK-targeted sites efficiently rescued the phenotype of p27-null cells. All three phosphorylation sites on Cortactin appear to act synergistically as the phenotype caused by the triple mutants (Cortactin TA and TD) was more profound than that of mutating S113 alone. While mimicking the phosphorylation of Cortactin on PAK1-targeted sites clearly causes the disassembly of invadopodia ([@bib57]; [@bib92]), the mechanism involved is still unclear but may be due to decreased affinity of Cortactin phosphorylated within its Actin-binding repeats for F-Actin, which may destabilize invadopodia ([@bib93]).

Results from [@bib57] and the present study show that inhibition of the Trio/Rac1/PAK1/Phospho-Cortactin pathway stabilizes invadopodia and is associated with a dramatic increase in proteolytic degradation of ECM. Surprisingly, this phenotype is accompanied by a sharp decrease in the ability of cells to invade through matrix in 3D invasion assays. Thus, it appears that the turnover of invadopodia rather than elevated ECM degradation is required for efficient invasion. Affecting the dynamics of invadopodia formation, maturation and disassembly is therefore detrimental to invasion, as observed here when this last step is inhibited by interfering with Rac1/PAK1 signaling or when p27 is absent. Interestingly, p27 also regulates cell migration in a similar manner by interfering with RhoA activation by its GEFs ([@bib4], [@bib5]). In absence of p27, cells accumulate actins stress fibers and focal adhesions and exhibit a migration defect due to an imbalance in the dynamic cycles of RhoA activation and inactivation (and concomitant Rac1 inactivation and activation) required for F-actin turnover, focal adhesion disassembly and efficient migration ([@bib4], [@bib5]; [@bib74]; [@bib1]; [@bib19]; [@bib78]; [@bib89]). Migration and invasion are two intimately linked processes ([@bib24]; [@bib71]). It is quite remarkable that p27 appears to regulate both of these processes, although by distinct mechanisms. Indeed, p27 binds to RhoA and Cortactin via the same domain located within the last 8 aa of the protein ([Figure 1E](#fig1){ref-type="fig"}) ([@bib41]; [@bib27]), but while RhoA preferentially binds p27 phosphorylated on T198 ([@bib41]), the interaction of p27 with Cortactin did not require the presence of T198 ([Figure 1E](#fig1){ref-type="fig"}), suggesting that different pools of the protein are involved in their regulation. In addition, the regulation of invadopodia by p27 did not appear to involve RhoA, as RhoA silencing affected both p27−/− and p27+/+ cells in a similar manner ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). p27 also regulates invasion by promoting EMT, notably through JAK2/STAT3 signaling and induction of the transcription factor Twist ([@bib99]).

We found that p27 binds to Cortactin on its actin-binding repeats and this interaction promoted the association of Cortactin with PAK1. Since we were unable to detect an interaction between p27 and PAK1 using either endogenous or overexpressed proteins, it remains unknown how p27 promotes the PAK1/Cortactin interaction. Evidence suggest that Cortactin is an intrinsically disordered protein (IDP), especially its actin-binding repeats ([@bib87]) and p27 is a well-known IDP ([@bib25]; [@bib39]; [@bib68]). Since these proteins typically fold upon binding to their partners, an attractive possibility is that p27 binding causes a conformation change in Cortactin that would favor its interaction with PAK1.

p27 is a cyclin-CDK inhibitor and although p27 regulates migration and invasion in a CDK-independent manner ([@bib5]; [@bib41]; [@bib99]; [@bib28]), there is evidence to suggest that some cell cycle independent roles of CDKs and cyclins may be mediated via CDK inhibitors such as p27 ([@bib29]). For instance, the regulation of cell migration by Cyclin D1 requires p27 ([@bib43]) and the role of CDK5 in promoting neuronal progenitor migration in vivo is mediated via the phosphorylation of p27 on Ser10 which regulates the RhoA/ROCK/LIMK/Cofilin pathway ([@bib62]; [@bib35]). Interestingly, CDK5 was recently found to play an important role in invadopodia formation and cancer cell invasion, and CDK5 inhibition blocked both these processes ([@bib73]; [@bib10]). CDK5 phosphorylated Caldesmon, causing its degradation by the proteasome and promoting invadopodia formation and invasion ([@bib73]). Since p27 is a poor inhibitor of CDK5 complexes ([@bib40]; [@bib42]), it would be interesting to test whether this role of CDK5 may involve p27. Indeed, an attractive hypothesis is that p27 could simultaneously interact with CDK5 complexes, via its N-terminal cyclin-CDK binding domain, and with Cortactin via its C-terminus, thereby recruiting CDK5 in proximity to Caldesmon bound to Cortactin and allowing Caldesmon phosphorylation.

Our study further defines the complex role played by p27 in the regulation of cytoskeletal dynamics, migration, EMT and invasion and provides another element to explain why the *Cdkn1b* gene is rarely mutated in cancer ([@bib16]; [@bib8]; [@bib33]). Indeed, p27 is either downregulated, mostly via increased proteasomal degradation, or excluded from the nuclei of cancer cells. Given that upon cytoplasmic relocalization, p27 promotes both migration and invasion and may serve to coordinately regulate these processes, it appears likely that this feature may be selected for during tumor progression and could participate in the acquisition of a metastatic behavior by cancer cells.

Materials and methods {#s4}
=====================

Antibodies, reagents and plasmids {#s4-1}
---------------------------------

Mouse anti c-Myc (9E10, sc-40, RRID:[AB_627268](https://scicrunch.org/resolver/AB_627268)), p27 (F8, sc-1641, RRID:[AB_628074](https://scicrunch.org/resolver/AB_628074)), p27 (SX53G8.5, sc-53871, RRID:[AB_785029](https://scicrunch.org/resolver/AB_785029)), αPAK (A6, sc-166887, RRID:[AB_10609226](https://scicrunch.org/resolver/AB_10609226)), RhoA (26C4, sc-418, RRID:[AB_628218](https://scicrunch.org/resolver/AB_628218)) and rabbit anti p27 (C19, sc-528, RRID:[AB_632129](https://scicrunch.org/resolver/AB_632129)), Myc (A14, sc-789, RRID:[AB_631274](https://scicrunch.org/resolver/AB_631274)), Cortactin (H191, sc-11408, RRID:[AB_2088281](https://scicrunch.org/resolver/AB_2088281)), Tks5 (M-300, sc-30122, RRID:[AB_2254551](https://scicrunch.org/resolver/AB_2254551)), αPAK (N-20, sc-882, RRID:[AB_672249](https://scicrunch.org/resolver/AB_672249)), Arp2 (H-84, sc-15389, RRID:[AB_2221848](https://scicrunch.org/resolver/AB_2221848)), c-Src (SRC2, sc-18, RRID:[AB_631324](https://scicrunch.org/resolver/AB_631324)) and ERK1 (K-23, sc-94, RRID:[AB_2140110](https://scicrunch.org/resolver/AB_2140110)) antibodies were purchased from Santa Cruz Biotechnology. Mouse anti p27 (610242), Grb2 (610112, RRID:[AB_397518](https://scicrunch.org/resolver/AB_397518)), Cortactin (610050, RRID:[AB_397462](https://scicrunch.org/resolver/AB_397462)), phopsho-Ser (612547, RRID:[AB_399842](https://scicrunch.org/resolver/AB_399842)) and Rac1 (610650, RRID:[AB_397977](https://scicrunch.org/resolver/AB_397977)) antibodies were purchased from BD-Transduction Laboratories. Mouse anti β-actin (A2228, RRID:[AB_476697](https://scicrunch.org/resolver/AB_476697)) antibody was purchased from Sigma-Aldrich. Rabbit anti phospho-Ser144-PAK1/phospho-Ser141-PAK2 (\#2606, RRID:[AB_2299279](https://scicrunch.org/resolver/AB_2299279)) antibody was purchased from Cell Signalling Technology. Rabbit anti acetyl-Cortactin (\#09--881, RRID:[AB_10584980](https://scicrunch.org/resolver/AB_10584980)) antibody was purchased from Millipore. Secondary antibodies against whole Ig or Ig light-chain conjugated to horseradish peroxydase or Cyanine-2--3 and −5 were from Jackson ImmunoResearch (RRID:[AB_10015282](https://scicrunch.org/resolver/AB_10015282), RRID:[AB_2340612](https://scicrunch.org/resolver/AB_2340612), RRID:[AB_2307443](https://scicrunch.org/resolver/AB_2307443), RRID:[AB_2340607](https://scicrunch.org/resolver/AB_2340607), RRID:[AB_2340770](https://scicrunch.org/resolver/AB_2340770), RRID:[AB_2340826](https://scicrunch.org/resolver/AB_2340826), RRID:[AB_2340813](https://scicrunch.org/resolver/AB_2340813), RRID:[AB_2340819](https://scicrunch.org/resolver/AB_2340819), RRID:[AB_2339149](https://scicrunch.org/resolver/AB_2339149), RRID:[AB_2338512](https://scicrunch.org/resolver/AB_2338512)).

siRNA control (D-001810-10-05), ON-TARGETplus Mouse Rac1 (19353) siRNA - SMARTpool (L041170000005) (\#2) and ON-TARGETplus Mouse PAK1 (18479) siRNA - SMARTpool (L048101000005) were from Dharmacon. mRac1 siRNA (\#1) (sc-36352), mRhoA siRNA (\#1) (sc-29471) and mRhoA siRNA (\#2) (sc-36414) were purchased from Santa Cruz Biotechnologies.

FRAX597 and Y-27632 were purchased from Selleckchem. NSC23766 was purchased from Tocris Biosciences. FRAX1036 and G-5555 were purchased from MedChemExpress.

p27 constructs and p27 point mutants and deletion mutants in pCS2+, pGEX4T1 (Pharmacia), pET16b (Novagen), pcDNA3.1 Hygro (Invitrogen) or pQCXIP (Clontech) were described previously ([@bib5]; [@bib84]). The Myc-tagged full-length and deletion mutants of mouse Cortactin (WT, ΔABR6, ΔABR5-6, ΔABR4-6, ΔABR3-6, ΔABR, ΔABR/NTA and ΔSH3) in pME18S vector were described previously ([@bib34]). Full length human Cortactin was cloned by RT-PCR from IMR90 mRNA and inserted into the pcDNA3.1 Hygro Myc vector. Full-length mouse Cortactin, Cortactin S113A and Cortactin S113D were kindly provided by Dr. Alan Mak (Queen's University, Kingston, Canada) ([@bib93]) and subcloned into pQCXIP. Cortactin TA (S113A, S150A and S282A) and TD (S113D, S150D and S282D) were generated by site-directed mutagenesis from the pQCXIP-Cortactin-S113A and pQCXIP-Cortactin-S113D vectors, respectively. GFP-Tks5, kindly provided by Dr. Frederic Saltel (INSERM UMR1053, Bordeaux), was subcloned into the pQCXIP vector. pCMV6-Myc-hPAK1 was kindly provided by Dr Jonathan Chernoff (Fox Chase Cancer Center, Temple Health, Philadelphia; Addgene \#12209). pGEX2TK-PAK-CD was kindly provided by Dr. John Collard (The Netherlands Cancer Institute, Amsterdam, The Netherlands). pEBB-Src-SH3-2 encoding the second SH3 domain of Nck1 fused to the myristoylation sequence of Src (myr-SH3-2) was a gift from Dr Bruce Mayer (University of Connecticut, Farmington). All plasmids used in this study were verified by sequencing.

Cell culture and transfections {#s4-2}
------------------------------

Primary MEFs were prepared as described previously ([@bib77]; [@bib5]) from p27+/+, p27CK−/CK− or p27−/− embryos. MEFs were immortalized by infection with retroviruses encoding the human papilloma virus E6 protein and hygromycin selection. HeLa (RRID:[CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)), HEK 293 (RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)), A-375 (RRID:[CVCL_0132](https://scicrunch.org/resolver/CVCL_0132)) and A549 (RRID:[CVCL_0023](https://scicrunch.org/resolver/CVCL_0023)) cells were obtained from Cell Lines Services. These cells were authenticated by short tandem repeat profiling. All cells were routinely tested to be free of mycoplasma contamination by DAPI staining.

All cells were grown at 37°C and 5% CO~2~ in DMEM (Sigma), 4.5 g/l glucose supplemented with 10% fetal calf serum, 0.1 mM nonessential amino acids and 2 µg /ml penicillin-streptomycin. When indicated, tissue culture vessels were coated with 0.2% gelatin from bovine skin (Sigma G1393) for 1 hr. MEFs were infected with different plasmids using retroviruses produced in Phoenix ecotropic cells transfected by the calcium phosphate method. HEK293 cells were also transfected by the calcium phosphate method for 24 hr. HeLa cells were transfected using JetPrime (Polyplus transfection) according to manufacturer's instructions. For siRNA transfections in MEF E6 cells, we used Interferin (Polyplus transfection) according to manufacturer's instructions.

Immunoprecipitation and GST pull-down {#s4-3}
-------------------------------------

Cells were scraped and lysed in IP buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween20, 10% glycerol and 1% NP-40 complemented with 1 mM DTT, 10 mM β-glycerophosphate, 10 mM NaF, 10 mM sodium orthovanadate, 10 µg/ml Aprotinin, 10 µg/ml Bestatin, 10 µg/ml Leupeptin and 10 µg/ml Pepstatin A. After sonication for 10 s, cells extracts were centrifuged for 5 min at 12,500 g and supernatants were collected. Lysates (300 µg for MEF E6 and HeLa, 500 µg for HEK293) were incubated with 3 µg of indicated antibodies and 12 µl protein-A sepharose beads (IPA300, Repligen) (co-immunoprecipitation) or with recombinant GST proteins and glutathione sepharose beads (Pharmacia) (GST pull-down) at 4°C for 4 hr. Beads were then washed four times in lysis buffer and resuspended in 10 µl 4X sample buffer, boiled, and subjected to western blotting.

Rac1-GTP pull-down assay {#s4-4}
------------------------

Pull-down assays for Rac1 activity were performed as described previously ([@bib5]; [@bib80]; [@bib53]). Briefly, E6 MEFs in 100 mm plates were washed with ice-cold PBS, scraped off the plates in 400 μl cell-lysis buffer (50 mM Tris-HCl at pH 7.4, 2 mM MgCl2, 1% NP-40, 10% glycerol, 100 mM NaCl, complemented with 1 mM dithiothreitol, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 10 μg/ml pepstatin-A) on ice. Lysates were centrifuged for 5 min at 14,000 rpm at 4°C. Three hundred μl of cleared lysates were incubated for 30 min at 4°C with 8 μl of GST--PAK-CD bound to glutathione-coupled Sepharose beads (at ∼1 μg GST fusion protein per μl of beads). Bead pellets were washed three times with ice-cold cell lysis buffer, resuspended in 4X sample buffer, and subjected to SDS-PAGE as described below. Ten μl of cell lysates were used for protein loading.

Immunoblot {#s4-5}
----------

Cells were lysed in IP buffer as described above. Lysates and immunoprecipitates were mixed with 4X sample buffer and boiled. Proteins were resolved on 8--15% SDS-PAGE (depending on protein size) and transferred to polyvinylidene difluoride membrane (Immobilon-P, Millipore). Membranes were blocked with PBS-T (PBS, 0.1% Tween-20), 5% non-fat dry milk and probed with indicated primary antibodies overnight at 4°C with gentle agitation. Membranes were washed three times in PBS-T then incubated with corresponding HRP-conjugated secondary antibody (1/10000) for 4 hr at room temperature. Bands were visualized using enhanced chemiluminescence detection reagents (Millipore, BioRad, Ozyme) and autoradiographic film (Blue Devil).

Gelatin degradation assay {#s4-6}
-------------------------

Coverslips were cleaned overnight in 1 M HCl, washed four times in ddH~2~O and then coated successively with 50 μg/ml Poly L-lysine, 0.5% glutaraldehyde, fluorescent gelatin (1:10 mix of gelatin from pig skin Oregon green 488 conjugate \[G13186, Molecular Probes\] and 0.2% gelatin from bovine skin \[Sigma G1393\]), and 5 mg/ml sodium borohydride. Between each coating, coverslips were washed three times with PBS. Coverslips were then sterilized with 70% ethanol and cells were seeded and incubated either overnight or 48 hr before fixation and staining.

Immunofluorescence {#s4-7}
------------------

Cells were seeded on coverslips coated as described above with only non fluorescent gelatin and grown overnight. When indicated, cells were permeabilized with 20 μg/ml digitonin in PBS for 2 min before fixation. Cells were fixed with 2% PFA in PBS for 20 min at 37°C. For immunostaining, cells were permeabilized for 3 min with PBS 0.2% Triton X-100, rinsed three times in PBS and incubated for 20 min in blocking solution (PBS, 3% BSA, 0,05% Tween20 and 0,08% sodium azide) and with primary antibodies diluted in blocking solution for 1 hr. After three washes of 5 min in PBS, cells were incubated for 30 min at 37°C with Cy-2 Cy-3 or Cy-5 conjugated secondary antibodies at 1:500 dilutions. Coverslips were washed 3 times for 5 min in PBS with the first wash containing 0.1 μg/ml Hoechst H33342 and mounted on glass slides with gelvatol (20% glycerol (v/v), 10% polyvinyl alcohol (w/v), 70 mM Tris pH 8). Images were captured on a Nikon 90i Eclipse microscope using a DS-Qi2 HQ (Nikon) camera and the NIS Element software.

For live cell imaging, MEFs infected with pQCXIP-Tks5-GFP were seeded in gelatin-coated wells overnight and placed in a controlled atmosphere chamber (37°C and 5% CO~2~) for imaging. Images were acquired every 2 min with a Zeiss Cell Observer microscope for 8 hr. Image analysis was performed with Image J/Fiji.

Migration assays {#s4-8}
----------------

Cells were seeded in gelatin coated 96-well plates (Essen ImageLock, Essen Bioscience) at 80% confluence and incubated overnight to allow them to reach confluence. Cells were treated for 2 hr before wounding with 2 μg/ml mitomycin C (M4287, Sigma) to block cell proliferation and scratches were performed in the cell monolayer using the wound maker (Essen Bioscience). Cells were washed immediately three times with PBS and re-fed with growth medium. Cell migration was monitored with an Incucyte FLR Live-Cell imaging system equipped with a 20X objective (Essen Bioscience). Images were acquired every 3 hr for 48 hr. Migration was quantified by measuring the relative wound density of at least three biological replicates in each experiment, using the Incucyte software (Essen Bioscience) as recommended by the manufacturer.

Invasion assays {#s4-9}
---------------

Fifty μl of 1 mg/ml of rat tail Collagen I (354236, Corning) solution were incubated for 1 hr at room temperature in 8 μm pores transwell inserts in 24-well plates (\#353097, Corning) to allow gelling of collagen. The gel was hydrated with DMEM-50% FCS for 3 hr at 37°C. Cells were incubated for 3 hr with 2 μg/ml Mitomycin C, washed twice with DMEM 0.1% FCS, trypsinized, counted and 30,000 cells were seeded in the transwell upper chamber in 100 μl of DMEM 0.1% FCS, with 600 μl of DMEM 10% FCS in the bottom chamber. Plates were incubated for 48 hr at 37°C and 5% CO~2~. At the end of the assay, the content of the top chamber was removed with a cotton swab and cells that invaded onto the bottom membrane of the transwell were quantified by XTT staining with 200 μg/ml XTT (Santa-Cruz Biotechnology, sc-258336) previously activated by adding 25 μM phenazine methosulfate (Sigma, P9625) in DMEM 10% FCS for 4 hr at 37°C. Absorbance was read at 450 nm. Cells were then fixed for 5 min in 95% ethanol/5% acetic acid and stained overnight with hematoxylin to capture images of invaded cells.

Statistical analyses {#s4-10}
--------------------

Statistical analyses were performed using Graphpad Prism 6.0 software. Differences between groups were evaluated using 1-way ANOVA followed by Bonferroni test for multiple comparison and considered significant when p\<0.05. Data are presented as mean ± SEM.

Mass spectrometry analyses {#s4-11}
--------------------------

HEK293 cells were transfected either with human Myc-tagged Cortactin or Myc-Cortactin and Myr-SH3-2 (that activates PAK1) for 24 hr. Cortactin was immunoprecipitated from lysates from four 100 mm plates per IP using 12 μg per IP of Mouse anti-Myc 9E10 antibody. Samples were separated on 12% SDS-PAGE. Gel was stained with instant blue for 1 hr. Amounts of immunoprecipitated Cortactin was estimated to 4 ug for each IP by comparison with a BSA standard on the same gel. Bands of interest were cut and placed in eppendorf tubes in 30 μl of 1% acetic acid solution and stored at −20C until MS/MS analysis.

### Protein digestion {#s4-11-1}

Excised gel bands were treated to remove salts, buffers and detergent using 3 washes of 50 mM NH~4~HCO~3~ intercalated with gel shrinkages in 50% acetonitrile (ACN). Disulfide bonds were disrupted with 20 mM DTT at 56°C for 30 min and subsequently alkylated in 55 mM chloroacetamide for 30 min at room temperature. A last wash with 50% ACN and 50 mM NH~4~HCO~3~ was performed before addition of 50 ng of trypsin (Promega Sequencing Grade) for an overnight digestion on an Eppendorf Thermomix at 30°C. Peptides were then extracted using 2 washes of 1% formic acid intercalated with gel shrinkages in 50% ACN. The two washes were pooled and evaporated before analysis.

### LC-MS/MS {#s4-11-2}

20% of each sample was analyzed in LC-MS-MS using an Ultimate 3000 Rapid Separation liquid chromatographic system coupled to an Orbitrap Fusion mass spectrometer (both from Thermo Fisher Scientific). Peptides were directly loaded on a C~18~ reverse phase analytical column (2 µm particle size, 100 Å pore size, 75 µm internal diameter, 50 cm length) with a 45 min effective gradient from 99% A (0.1% formic acid and 100% H2O) to 50% B (80% ACN, 0.085% formic acid and 20% H2O). The Orbitrap Fusion mass spectrometer acquired data throughout the elution process and operated in a data dependent scheme with full MS scans acquired with the orbitrap, followed by stepped HCD MS/MS (top speed mode in 3 s) on the most abundant ions detected in the MS scan. Mass spectrometer settings were: full MS (AGC: 4.0E^5^, resolution: 120,000, m/z range 350--1500, maximum ion injection time: 60 ms); MS/MS was performed using Stepped HCD Normalized Collision Energy at 30 plus and minus 5%, Orbitrap resolution was set at 17500, intensity threshold: 1.0E^4^, isolation window: 1.6 m/z, dynamic exclusion time setting: 30 s, AGC Target: 1.0E^4^ and maximum injection time: 100 ms). The fragmentation was permitted of precursor with a charge state of 2 to 4. The software used to generate. mgf files is Proteome discoverer 1.4.

### Peptide identification {#s4-11-3}

Mass list were used to perform comparison of MS/MS experimental peak lists with the *Homo sapiens* taxon of the Swiss-Prot database (November 2016, 20,204 sequences) using Mascot version 2.5.1 ([@bib70]). The cleavage specificity set was the trypsin with maximum four missed cleavages. The precursor mass tolerance was set to 4 ppm and the MS/MS mass tolerance to 0.55 Da. Cystein carbamidomethylation was set as a constant modification while methionine oxidation, tyrosine, serine and threonine phosphorylation were set as variable modification. With these settings, peptide identifications were considered as valid whenever their scores reached a minimum of 23, thus meeting the *p*-values criteria less than 0.05.
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\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"p27^Kip1^ promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Fiona Watt as the Senior Editor.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

This study demonstrates that p27 binding to Cortactin promotes PAK1 interactions with Cortactin, and invadopodia disassembly by phosphorylation of Cortactin on Ser-113. Biochemical analysis is presented to support these conclusions, including the demonstration that a phosphomimetic mutant of Cortactin can complement the p27 deficiency phenotype on invadopodia disassembly. Together, these aspects of the manuscript represent significant strengths. However, the detailed reviews (appended) identify a number of weaknesses in the data used to support the presented conclusions. Given the extensive new experimentation that will be required to address these weaknesses, a decision to reject your manuscript was made. Please be assured that *eLife* is interested in this area of research. Indeed, we would welcome the submission of a new manuscript on this topic when findings from new experimentation are obtained.

Reviewer \#1:

This study demonstrates that p27 binding to Cortactin promotes PAK1 interactions with Cortactin, and invadopodia disassembly by phosphorylation of Cortactin on Ser-113. In general, the biochemical analysis is strong and convincing. Indeed, the demonstration that a phosphomimetic mutant of Cortactin can complement the p27 deficiency phenotype on invadopodia disassembly is very interesting. However, there are a number of areas that require strengthening.

1\) The siRNA studies (Rac and RhoA) were performed with a single oligonucleotide. To exclude off0target effects, phenotypes should be confirmed with two independent siRNAs.

2\) Some care should be taken concerning the PAK1/Cortactin connection. First, the studies presented are focussed on mutational analysis of the Cortactin phosphorylation site Ser-113 rather than the kinase. Second, in vitro studies demonstrate phosphorylation of Cortactin by PAK3 at more than one site (Webb et al.). Third, what is the evidence that PAK1 phosphorylates Cortactin in vivo? Fourth, the in vivo studies are reliant on a drug.

3\) The conclusion that p27 regulates Cortactin/PAK mediated invadopodia disassembly are based on static images of invadopodia number. Conclusions about the dynamic nature of invadopodia would be best supported by images documenting the dynamics.

Reviewer \#2:

This work, building on prior publications from Webb et al. and Moshfegh et al., 2014 attempts to provide a mechanistic basis for the effects of cytosolic p27 on invadopodia dynamics and cell invasion. For the most part, the data appear sound, but there are a few key issues that are not adequately addressed.

1\) The only experiment that identifies Pak1 as a link between p27 and invadopodia is treatment of MEFs with FRAX597 ([Figure 6](#fig6){ref-type="fig"}). There are two issues here: this compound affects all three group A Paks (thus one can\'t say the effects are through Pak1) and FRAX597 has poor selectivity towards STE20 kinases such as Group A Paks as compared to tyrosine kinases. There are much more selective compounds (e.g., FRAX1036 and G5555) as well as other approaches (siRNA, CRISPR) that could and should be used to establish the link claimed by the authors. As things stand, the data do not adequately support the author\'s contentions.

2\) There really isn\'t any proof that Cortactin gets phosphorylated by Pak at S113, only that substitutions at this residue affect invadopodia dynamics ([Figure 7](#fig7){ref-type="fig"}). What would have made the case much stronger are phospho-S113 blots and/or IFs showing that phosphorylation of this site is modulated by Rac/Pak. As far as I can tell, the initial paper from Webb et al., 2006, on which the present manuscript relies, only provided in vitro evidence that recombinant Pak3 could phosphorylate Cortactin at S113. As there are no available phospho S113 antibodies, the authors might instead IP Cortactin from p27-/- MEFs and blot with p-Ser antibodies or, better, ID sites by mass spec. I know this sort of experiments isn\'t fun or easy, but the use of phospho-mimics alone is not adequate to support their conclusions.

Reviewer \#3:

This manuscript identifies p27^kip1^ as a regulator of invadopodia formation and cell invasion, increasing the surprising number of cellular processes known to be regulated by this protein. While cytoplasmic p27^kip1^ was previously established to limit RhoA activity and stress fiber formation to promote cell migration, Jeannot et al., 2015 describe a new mechanism, where p27 promotes Cortactin phosphorylation by Pak1 to reduce invadopodia and increase cell invasion through collagen. While the authors include a strong set of experiments that convincingly demonstrates a p27/Cortactin/PAK1 pathway exists, the manuscript overall feels somewhat preliminary because it is not clear how inhibition of this pathway can increase invadopodia formation and prevent cell invasion. Presenting a mechanism to explain this puzzling observation and more clearly demonstrating p27 is localized to matrix degrading structures would strengthen the novel, and important conclusions made by the authors. Additional concerns are listed below.

Major Concerns:

The pre-fixation permeabilization/extraction of the cytoplasm prior to staining for p27 does not give a lot of confidence that p27 is localized to invadopodia (as in [Figure 2A](#fig2){ref-type="fig"}, for example). Additionally, the Cortactin phosphomimetic construct decreases the number of invadopodia without significantly reducing the area of gelatin degradation, raising the strong possibility that the structures being identified by Cortactin (eg. [Figure 3A](#fig3){ref-type="fig"}) are not actual invadopodia, despite their punctate appearance. To make confirm these structures are invadopodia, the authors should show p27 is enriched in Cortactin or Tsk5 positive puncta which coincide with regions of matrix degradation.

The authors\' measure number of cells with invadopodia (eg. [Figure 3B](#fig3){ref-type="fig"}), yet often conclude that cells have more invadopodia. If the authors are going to conclude that there are more invadopodia per cell, this is something that must be explicitly measured.

Importantly, the strikingly counterintuitive conclusion that increasing invadopodia inhibits invasion was not sufficiently justified. It remains a possibility that another pathway mediated by p27 is responsible for the invasion phenotype. One way to address this possibility would be to show expression of p27 1-190 is unable to rescue cell invasion.

It is not clear if the migration defect resulting from loss of p27Kip (Besson et al., 2006), is mechanistically distinct from the invasion phenotype reported here. In their previous publication, it was shown that inhibition of Rho kinase rescued migration. Does Rho kinase inhibition also restore the ability of the p27 -/- cells to invade through thin collagen layers? If not, it would strengthen the conclusion that the authors are investigating a novel migration mechanism downstream of p27^kip1^.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"p27^Kip1^ promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Fiona Watt (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) While the colocalization of p27 and Tks5 in regions of degraded gelatin is now included in the manuscript, increasing confidence that these structures are bona fide invadopodia, it is not clear how specific the colocalization is compared to regions of the cell that are not associated with regions of gelatin degradation. I suggest the authors include line scans of regions of the cell not associated with gelatin degradation to demonstrate the specificity and import of the colocalization they now measure near regions of degraded gelatin.

2\) It is not clear if statistical tests were performed on the data presented in [Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}, [Figure 5 C and E](#fig5){ref-type="fig"}, and [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"p27^Kip1^ promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Fiona Watt (Senior editor) and a Reviewing editor.

The manuscript has been improved but there is one minor issue that needs to be addressed before acceptance. The new statistical analysis of [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} stated in the figure legends indicates that differences are not significant. However, in the text referring to these figures, it is stated that increases were observed. This is contradictory. Please clarify.

10.7554/eLife.22207.040

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Reviewer \#1:

This study demonstrates that p27 binding to Cortactin promotes PAK1 interactions with Cortactin, and invadopodia disassembly by phosphorylation of Cortactin on Ser-113. In general, the biochemical analysis is strong and convincing. Indeed, the demonstration that a phosphomimetic mutant of Cortactin can complement the p27 deficiency phenotype on invadopodia disassembly is very interesting. However, there are a number of areas that require strengthening.

1\) The siRNA studies (Rac and RhoA) were performed with a single oligonucleotide. To exclude off0target effects, phenotypes should be confirmed with two independent siRNAs.

To strengthen the data obtained with single siRNAs for Rac1 and RhoA, we have repeated these experiments (\# of cells forming invadopodia and area degraded/cell) with a pool of 4 siRNA against Rac1 (ON-TARGETplus Mouse Rac1 siRNA -- SMARTpool (L041170000005)) and with a new pool of 3 siRNAs against RhoA (sc-36414). These results have been incorporated into [Figure 7B-D](#fig7){ref-type="fig"} for Rac1 and [Figure 7---figure supplement 1A-C](#fig7s1){ref-type="fig"} for RhoA. In addition, siRac1 results are also replicated using a pharmacological inhibitor of Rac1 ([Figure 7E-F](#fig7){ref-type="fig"}), arguing against an off-target effect of the siRNA.

*2) Some care should be taken concerning the PAK1/Cortactin connection. First, the studies presented are focussed on mutational analysis of the Cortactin phosphorylation site Ser-113 rather than the kinase. Second,* in vitro *studies demonstrate phosphorylation of Cortactin by PAK3 at more than one site (Webb et al.). Third, what is the evidence that PAK1 phosphorylates Cortactin* in vivo*? Fourth, the* in vivo *studies are reliant on a drug.*

We have modified the text and use more careful wording when describing the PAK1/Cortactin connection. We also have taken several steps to strengthen this point:

1\) To investigate the importance of PAK1, we had data using the FRAX597 inhibitor, which targets the ATP-binding pocket in the kinase domain of PAK1-3 and inhibits the kinase activity of PAK, therefore suggesting that the kinase activity of PAK is involved.

As suggested by reviewer 2, we replicated these experiments (\# of cells forming invadopodia and area degraded/cell) and with other, more specific inhibitors, of PAK1-3 (FRAX1036 and G5555). These inhibitors gave similar results as FRAX597, thus confirming the importance of PAK activity in p27-mediated control of invadopodia dynamics. This data has been included in the manuscript as [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.

Since these inhibitors cannot discriminate between PAK1-3, we also performed similar experiments with siRNAs (a pool of 4 siRNAs) against PAK1 (ON-TARGETplus Mouse PAK1 (18479) siRNA -- SMARTpool (L048101000005). Results with PAK1 siRNA are similar to those obtained with PAK pharmacological inhibitors, supporting the involvement of PAK1 in the pathway we describe. These data have been included in [Figure 6A-C](#fig6){ref-type="fig"}.

Altogether, we now have data from 3 different PAK1-3 pharmacological inhibitors and from PAK1-specific siRNA that give similar results, thus strongly suggesting that PAK1 is indeed involved in the pathway regulating invadopodia dynamics.

2\) Webb and colleagues (2006) have reported the phosphorylation of Cortactin by PAK3 in vitro on three different residues (S113, S150 and S282).

As suggested by the reviewer, we tested whether the other sites known to be phosphorylated by PAK on Cortactin were important in the phenotype observed, We generated triple S113/S150/S282 unphosphorylatable and phosphomimetic Cortactin mutants and measured the effect on \# of cells forming invadopodia and area degraded/cell. Triple mutants give similar results as S113 Cortactin mutants, with a stronger effect of the triple unphosphorylatable mutant in p27+/+ cells (13.5% cells forming invadopodia with S113A versus 23.3% with tripleA mutant; 6.17 fold increased area degraded with S113A versus 10.02 fold with TripleA) suggesting that these sites (or at least one of them) also contribute to Cortactin regulation of invadopodia dynamics. These results have been included in [Figure 7F-J](#fig7){ref-type="fig"}. These results also reinforce the idea that phosphorylation of Cortactin is important in the control of invadopodia dynamics.

3\) We now provide 4 lines of evidence indicating that these sites are indeed phosphorylated in vivo:

a\) By IP Cortactin and anti Phospho-Ser immunoblot we found that Ser phosphorylation of Cortactin was reduced in presence of PAK1-3 inhibitor FRAX597. This data is provided as [Figure 8---figure supplement 1A and B](#fig8s1){ref-type="fig"}.

b\) By IP Cortactin and anti Phospho-Ser immunoblot we found that expression of Cortactin S113A and Cortactin S113A/S150A/S282A exhibit decreased phospho-Ser signal compared to wild-type Cortactin, arguing that phosphorylation of these sites contribute to the phospho-Ser signal detected. This data is provided as [Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}.

c\) Our initial attempt to obtain mass spectrometry data showing that Cortactin was phosphorylated in vivo was with a private company. We since established a collaboration with a group specialized in MS work at the Institut Cochin. We were able to detect a phosphorylation of Cortactin at Ser150 (one of the 3 sites reported to be phosphorylated by PAK1-3) when a myristoylated form of the second SH3 domain of Nck1 was co-expressed (previously shown to activate PAK1 by Bruce Mayer\'s lab: Lu et al., 1997 and Lu and Mayer, 1999) but not when only Cortactin was expressed. Therefore PAK activation in these cells appear to induce Cortactin S150 phosphorylation. This mass spectrometry data is provided as [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.

d\) Database mining (PhosphositePlus) shows that Cortactin phosphorylation on S113, S150 and/or S282, the three sites targeted by PAK1-3, has previously been detected in vivo by mass spectrometry and this is described in 8 publications of global proteome analyses:

1\) Chen et al., J Proteome Res 2010, 9:174-8

Shows Cortactin S113 phosphorylation in LNCaP prostate cancer cells

2)Olsen et al., Sci Signal 2010, 3(104):ra3

Shows Cortactin S282 phosphorylation in mitotic cells

3\) Rinschen et al., PNAS 2010, 107: 3882-7

Shows Cortactin S150 phosphorylation in mpkCCD renal cells

4\) Wisniewski et al., J Proteome Res 2010, 9:3280-9

Shows Cortactin S113 phosphorylation in mouse brain

5\) Klammer et al., Mol Cell Proteomics 2012, 11: 651-88

Shows Cortactin S282 phosphorylation in breast tumors

6\) Bian et al., J Proteomics 2014, 96: 253-62

Shows Cortactin S150 phosphorylation in human liver

7\) Mertins et al., Mol Cell Proteomics 13: 1690-704

Show Cortactin S113, S150 and S282 phosphorylation in ovarian and breast xenograft tissues

8\) Mertins et al., Nature 2016, 534: 55-62

Shows Cortactin S113 and S282 phosphorylation in breast cancer

These references are now discussed in our revised manuscript.

We believe that the fact several other groups have reported the phosphorylation of those sites in vivo in various models in independent studies provides strong evidence that Cortactin is actually phosphorylated on these three sites in vivo.

4\) As detailed in point \#1, our in vivo studies are now relying on three different PAK1-3 pharmacological inhibitor as well as similar experiments performed with PAK1 siRNA treated cells.

3\) The conclusion that p27 regulates Cortactin/PAK mediated invadopodia disassembly are based on static images of invadopodia number. Conclusions about the dynamic nature of invadopodia would be best supported by images documenting the dynamics.

To strengthen our conclusions and provide direct evidence that p27 affects invadopodia stability, we determined invadopodia lifetime in p27+/+ and p27-/- MEFS by videomicroscopy using eGFP-Tks5. This data has been added as [Figure 5A](#fig5){ref-type="fig"} and shows that invadopodia in p27-/- cells have a longer lifetime than in p27+/+ cells.

Reviewer \#2:

This work, building on prior publications from Webb et al. and Moshfegh et al., 2014 attempts to provide a mechanistic basis for the effects of cytosolic p27 on invadopodia dynamics and cell invasion. For the most part, the data appear sound, but there are a few key issues that are not adequately addressed.

1\) The only experiment that identifies Pak1 as a link between p27 and invadopodia is treatment of MEFs with FRAX597 ([Figure 6](#fig6){ref-type="fig"}). There are two issues here: this compound affects all three group A Paks (thus one can\'t say the effects are through Pak1) and FRAX597 has poor selectivity towards STE20 kinases such as Group A Paks as compared to tyrosine kinases. There are much more selective compounds (e.g., FRAX1036 and G5555) as well as other approaches (siRNA, CRISPR) that could and should be used to establish the link claimed by the authors. As things stand, the data do not adequately support the author\'s contentions.

As suggested by the reviewer, we replicated these experiments (\# of cells forming invadopodia and area degraded/cell) with siRNAs against PAK1 and with the more specific inhibitors of PAK1-3, FRAX1036 and G5555, to better support the link between PAK1 and Cortactin in p27-mediated regulation of invadopodia dynamics. These results are provided in [Figure 6A-C](#fig6){ref-type="fig"} and in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.

*2) There really isn\'t any proof that Cortactin gets phosphorylated by Pak at S113, only that substitutions at this residue affect invadopodia dynamics ([Figure 7](#fig7){ref-type="fig"}). What would have made the case much stronger are phospho-S113 blots and/or IFs showing that phosphorylation of this site is modulated by Rac/Pak. As far as I can tell, the initial paper from Webb et al., 2006, on which the present manuscript relies, only provided* in vitro *evidence that recombinant Pak3 could phosphorylate Cortactin at S113. As there are no available phospho S113 antibodies, the authors might instead IP Cortactin from p27-/- MEFs and blot with p-Ser antibodies or, better, ID sites by mass spec. I know this sort of experiments isn\'t fun or easy, but the use of phospho-mimics alone is not adequate to support their conclusions.*

As suggested by the reviewer, we performed additional experiments indicating that:

a\) By IP Cortactin and anti Phospho-Ser immunoblot we found that Ser phosphorylation of Cortactin was reduced in presence of PAK1-3 inhibitor FRAX597. This suggests that PAK1-3 contribute to the phosphorylation of Cortactin. This data is provided as [Figure 8---figure supplement 1A and B](#fig8s1){ref-type="fig"}.

b\) By IP Cortactin and anti Phospho-Ser immunoblot we found that expression of Cortactin S113A and Cortactin S113A/S150A/S282A (the sites targeted by PAK) exhibit decreased phospho-Ser signal compared to wild-type Cortactin, arguing that phosphorylation of these sites contribute to the phospho-Ser signal detected. This data is provided as [Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}.

c\) Our initial attempt to obtain mass spectrometry data showing that Cortactin was phosphorylated in vivo was with a private company. We since established a collaboration with a group specialized in MS work at the Institut Cochin. We were able to detect a phosphorylation of Cortactin at Ser150 (one of the 3 sites reported to be phosphorylated by PAK1-3) when a myristoylated form of the second SH3 domain of Nck1 was co-expressed (previously shown to activate PAK1 by Bruce Mayer\'s lab: Lu et al., 1997 and Lu and Mayer, 1999) but not when only Cortactin was expressed. Therefore PAK activation in these cells appear to induce Cortactin S150 phosphorylation. This mass spectrometry data is provided as [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.

d\) Database mining (PhosphositePlus) shows that Cortactin phosphorylation on S113, S150 and/or S282, the three sites targeted by PAK1-3, has previously been detected in vivo by mass spectrometry and this is described in 8 publications of global proteome analyses:

1\) Chen et al., J Proteome Res 2010, 9:174-8

Shows Cortactin S113 phosphorylation in LNCaP prostate cancer cells

2\) Olsen et al., Sci Signal 2010, 3(104):ra3

Shows Cortactin S282 phosphorylation in mitotic cells

3\) Rinschen et al., PNAS 2010, 107: 3882-7

Shows Cortactin S150 phosphorylation in mpkCCD renal cells

4\) Wisniewski et al., J Proteome Res 2010, 9:3280-9

Shows Cortactin S113 phosphorylation in mouse brain

5\) Klammer et al., Mol Cell Proteomics 2012, 11: 651-88

Shows Cortactin S282 phosphorylation in breast tumors

6\) Bian et al., J Proteomics 2014, 96: 253-62

Shows Cortactin S150 phosphorylation in human liver

7\) Mertins et al., Mol Cell Proteomics 13: 1690-704

Show Cortactin S113, S150 and S282 phosphorylation in ovarian and breast xenograft tissues

8\) Mertins et al., Nature 2016, 534: 55-62

Shows Cortactin S113 and S282 phosphorylation in breast cancer

These references are now discussed in our revised manuscript.

Reviewer \#3:

This manuscript identifies p27^kip1^ as a regulator of invadopodia formation and cell invasion, increasing the surprising number of cellular processes known to be regulated by this protein. While cytoplasmic p27^kip1^ was previously established to limit RhoA activity and stress fiber formation to promote cell migration, Jeannot et al, 2015. describe a new mechanism, where p27 promotes Cortactin phosphorylation by Pak1 to reduce invadopodia and increase cell invasion through collagen. While the authors include a strong set of experiments that convincingly demonstrates a p27/Cortactin/PAK1 pathway exists, the manuscript overall feels somewhat preliminary because it is not clear how inhibition of this pathway can increase invadopodia formation and prevent cell invasion. Presenting a mechanism to explain this puzzling observation and more clearly demonstrating p27 is localized to matrix degrading structures would strengthen the novel, and important conclusions made by the authors. Additional concerns are listed below.

Major Concerns:

The pre-fixation permeabilization/extraction of the cytoplasm prior to staining for p27 does not give a lot of confidence that p27 is localized to invadopodia (as in [Figure 2A](#fig2){ref-type="fig"}, for example). Additionally, the Cortactin phosphomimetic construct decreases the number of invadopodia without significantly reducing the area of gelatin degradation, raising the strong possibility that the structures being identified by Cortactin (eg. [Figure 3A](#fig3){ref-type="fig"}) are not actual invadopodia, despite their punctate appearance. To make confirm these structures are invadopodia, the authors should show p27 is enriched in Cortactin or Tsk5 positive puncta which coincide with regions of matrix degradation.

We performed co-immunostaining for Tks5, p27 and fluorescent gelatin providing evidence that p27 and Tks5 colocalize in structures capable of degrading ECM. These data in p27+/+ MEFs and in A549 lung adenocarcinoma cells are now presented in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

We had some variability in the last set of experiments using S113 Cortactin mutants. More experiments have now been performed and these experiments have been incorporated in the existing figure panels, improving the quality of the data presented ([Figure 8B-E](#fig8){ref-type="fig"}). In addition, we now provide new data using Cortactin mutants in which the three sites reported to be phosphorylated by PAK (S113/S150/S282) have been mutated to either unphosphorylatable and phosphomimetic residues. The triple unphosphorylatable mutant (Cortactin TA) give more robust responses in p27+/+ cells (13.5% cells forming invadopodia with S113A versus 23.3% with tripleA mutant; 6.17 fold increased area degraded with S113A versus 10.02 fold with TripleA) suggesting that these sites have a synergistic effect in Cortactin regulation of invadopodia dynamics. This data is presented in [Figure 8F-J](#fig8){ref-type="fig"}.

The authors\' measure number of cells with invadopodia (eg. [Figure 3B](#fig3){ref-type="fig"}), yet often conclude that cells have more invadopodia. If the authors are going to conclude that there are more invadopodia per cell, this is something that must be explicitly measured.

We have modified the text to ensure that our conclusions are referring only to the number of cells forming invadopodia.

Importantly, the strikingly counterintuitive conclusion that increasing invadopodia inhibits invasion was not sufficiently justified. It remains a possibility that another pathway mediated by p27 is responsible for the invasion phenotype. One way to address this possibility would be to show expression of p27 1-190 is unable to rescue cell invasion.

As suggested by the reviewer, we performed invasion assays with p27-/- MEFs infected with either empty vector, p27CK- or p27CK- 1-190 mutants. While p27CK- expression clearly increased the invasive capacity of p27-/- cells, the p27CK- 1-190 mutant had no effect, thus confirming that the ability of p27 to interact with Cortactin is required for the regulation of invasion. This data is now presented in [Figure 4E](#fig4){ref-type="fig"}.

It is not clear if the migration defect resulting from loss of p27Kip (Besson et al., 2006), is mechanistically distinct from the invasion phenotype reported here. In their previous publication, it was shown that inhibition of Rho kinase rescued migration. Does Rho kinase inhibition also restore the ability of the p27 -/- cells to invade through thin collagen layers? If not, it would strengthen the conclusion that the authors are investigating a novel migration mechanism downstream of p27^kip1^.

As the reviewer suggested, we performed transwell invasion assays with cells treated with the ROCK inhibitor Y26632. ROCK inhibition had no effect on the invasive capacity of p27+/+ and p27-/- MEFs ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). This is in agreement with our data indicating that siRNAs against RhoA did not significantly affect the number of cells forming invadopodia and only slightly increased the ability of both p27+/+ and p27-/- MEFs to degrade ECM ([Figure 7---figure supplement 1A-C](#fig7s1){ref-type="fig"}), suggesting that the regulation of RhoA by p27 is not involved in this phenotype.

\[Editors\' note: the author responses to the re-review follow.\]

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) While the colocalization of p27 and Tks5 in regions of degraded gelatin is now included in the manuscript, increasing confidence that these structures are bona fide invadopodia, it is not clear how specific the colocalization is compared to regions of the cell that are not associated with regions of gelatin degradation. I suggest the authors include line scans of regions of the cell not associated with gelatin degradation to demonstrate the specificity and import of the colocalization they now measure near regions of degraded gelatin.

As requested, we added line scans on the same images not associated with regions of gelatin degradation and the results indicate that individual spots of Tks5 and p27 do not colocalize extensively outside of these regions of gelatin degradation. Two panels (C and D) have been added to [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} to illustrate this point.

2\) It is not clear if statistical tests were performed on the data presented in [Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}, [Figure 5 C and E](#fig5){ref-type="fig"}, and [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}.

Statistical analyses had not been performed on the graphs. We have now performed these analyses:

For [Figure 2C](#fig2){ref-type="fig"}, [Figure 2--- figure supplement 2B](#fig2s2){ref-type="fig"} and [Figure 5E](#fig5){ref-type="fig"}, the differences of each time-point with the control condition (time 0) were not significant. We added a sentence in the figure legends of these panels to mention that fact. For the graphs in [Figure 5B](#fig5){ref-type="fig"} and [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}, the differences were statistically significant (p\<0.01) and we added '\*\*' on the graphs and legends. All statistical analyses for these panels are now included in the source data files accompanying the manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

The manuscript has been improved but there is one minor issue that needs to be addressed before acceptance. The new statistical analysis of [Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} stated in the figure legends indicates that differences are not significant. However, in the text referring to these figures, it is stated that increases were observed. This is contradictory. Please clarify.

Original sentence:

"Consistent with the translocation of p27 in the cytoplasm and the formation of invadopodia after serum or growth factor stimulation, an increased amount of Cortactin co-immunoprecipitated with p27 at 1 h and 3 h post-stimulation in p27+/+ E6 MEFs ([Figure 2C](#fig2){ref-type="fig"}) and in Hela cells ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"})."

New sentence:

"Consistent with the translocation of p27 in the cytoplasm and the formation of invadopodia after serum or growth factor stimulation, an increased association between p27 and Cortactin by co-immunoprecipitation at 1 h and 3 h post-stimulation in p27+/+ E6 MEFs ([Figure 2C](#fig2){ref-type="fig"}) and in Hela cells ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) was observed in five and three independent experiments, respectively. However, due to variability in signal intensities among independent experiments, these differences were not statistically significant."
